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1. Summary 
 
Cutaneous melanoma is the most deadly skin cancer with a yearly rising incidence. The aggressiveness 
of this cancer is based on the stark metastatic potential of melanoma cells. Thus, melanoma patients 
usually die from metastatic disease rather than from primary tumor growth, which underscores the 
importance of studying mechanisms involved in melanoma cell dissemination and metastasis formation. 
Previously, the “phenotype switching” concept has been considered to be key for metastatic melanoma 
progression. In this model, melanoma cells have the capacity to dynamically switch between a 
proliferative and an invasive state. These are characterized by MITFhigh/AXLlow and MITFlow/AXLhigh 
expression, respectively. Among the signaling pathways that can drive reversible phenotype switching 
is SMAD-dependent TGF-β superfamily signaling. Importantly, the data describing the roles of 
phenotype switching and TGF-β signaling in melanoma have mostly been gathered by means of in vitro 
experiments and are somewhat controversial. Thus, it remains largely unknown to which extent 
phenotype switching and TGF-β superfamily signaling contribute to in vivo melanoma growth and 
metastasis. 
 
In my PhD thesis, I investigate the relevance of phenotype switching for melanomagenesis. In 
particular, I decipher the differential roles of TGF-β signaling during melanoma formation and 
metastatic progression. Using genetically engineered mouse models, I show for the first time that 
phenotype switching is not obligatory for melanoma cell invasion and metastasis. In melanoma, TGF-
β signaling has so far been associated with anti-proliferative and pro-invasive activities. Intriguingly, 
my results reveal that overall canonical TGF-β signaling, which depends on the co-SMAD protein 
Smad4, is required for tumor initiation and promotes, rather than antagonizes, melanoma cell 
proliferation in vivo. Consistent with these data, I identify BMP7 as a factor that stimulates melanoma 
cell proliferation and is able to override the anti-proliferative/pro-invasive activity of TGF-β. However, 
invasiveness can be promoted in proliferative cells by decreasing the levels of the inhibitory SMAD 
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protein SMAD7. Using genome-wide expression analyses of patient data and SMAD7-depleted 
melanoma cells, I further reveal that SMAD7 loss regulates both cell cycle progression as well as cell 
migration and adhesion. Thus, integrated TGF-β superfamily signaling during SMAD7 silencing 
propagates MITFhigh/AXLhigh cells that simultaneously proliferate while displaying an invasive gene 
expression signature. Likewise, conditional Smad7-inactivation in melanoma in vivo provokes 
emergence of such double positive cells, which ultimately leads to massive metastasis formation. 
In summary, my findings demonstrate that proliferation is compatible with increased invasiveness and 
reveal a novel mechanism underpinning melanoma aggressiveness. 
 
2. Zusammenfassung 
 
Schwarzer Hautkrebs (auch Melanom genannt) ist die tödlichste Form aller Hautkrebsarten, derweil die 
Häufigkeit von Melanomerkrankungen stetig zunimmt. Die Aggressivität dieser Krebsart rührt daher, 
dass Melanomzellen mühelos metastasieren. Aus diesem Grund sterben Melanompatienten meist nicht 
am Primärtumor sondern an den Metastasen. Deshalb ist es von zentraler Bedeutung, die Mechanismen 
zu studieren, welche zur Metastasenbildung beitragen. Es wird angenommen, dass während der 
Melanommetastasierung ein Prozess namens „Phänotyp-Umschaltung“ eine zentrale Rolle spielt. In 
diesem Modell können Melanomzellen dynamisch zwischen einem proliferierendem und einem 
invasivem Stadium hin und her wechseln. Diese zwei Zustände werden durch die Expression von 
MITFhigh/AXLlow, respektive MITFlow/AXLhigh, definiert. Eine zentrale, zelluläre 
Signaltransduktionskaskade, welche Phänotyp-Umschaltung induzieren kann, ist die SMAD abhängige 
TGF-β-Superfamilie-Signalkaskade. Viele der Daten, welche das Phänotyp-Umschaltungsmodell und 
die Rolle der TGF-β-Signalkaskade während der Melanomentwicklung untermauern sollten, basieren 
aber nur auf in vitro Experimenten und wiedersprechen sich teilweise. Ob die Phänotyp-Umschaltung 
und die TGF-β-Signalkaskade tatsächlich für die in vivo Entstehung und Metastasierung des Melanoms 
relevant sind, ist jedoch weitgehend unbekannt. 
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Während meines Doktorates habe ich die Relevanz des Phänotyp-Umschaltungsphänomen während der 
Metastasenbildung eruiert. Zudem habe ich die unterschiedlichen Rollen der TGF-β-Signalkaskade 
während dem Wachstum und der Metastasierung des Melanoms studiert. Mit der Verwendung von 
genetisch manipulierten Mäusen konnte ich zum ersten mal aufzeigen, dass Melanomtumoren 
metastasieren können, ohne auf die Phänotyp-Umschaltung zurückzugreifen. Die TGF-β-
Signalkaskade wurde traditionellerweise mit anti-proliferativen und pro-invasiven Kapazitäten von 
Melanomzellen in Verbindung gebracht. Meine Resultate zeigen jedoch auf, dass der gesamte Effekt 
der TGF-β-Signalkaskade, welche von dem co-SMAD Protein Smad4 abhängt, für die Proliferation von 
Melanomzellen relevant ist und dadurch die Melanomentstehung fördert. Im Rahmen dieser Resultate 
habe ich auch BMP7 als Faktor identifiziert, welcher die Proliferation von Melanomzellen stimuliert 
und den anti-proliferativen Effekt von TGF-β aushebelt. Durch die Unterdrückung des inhibitorischen 
SMAD Proteins SMAD7 kann jedoch wiederum die Invasivität von proliferierenden Melanomzellen 
angeheizt werden. Analysen von Patientendaten und Genexpressionsmustern haben aufgezeigt, dass 
sich in diesen Zellen die Expression von Proliferations- und von Invasionsgenen verändert. Dies führt 
dazu, dass sich durch die Auslöschung von SMAD7 Melanomzellen ansammeln, welche 
MITFhigh/AXLhigh sind und gleichzeitig proliferieren und invasive Verhaltensmuster zeigen. Durch die 
Deletion des Smad7 Genes in Mäusen habe ich auch die Ansammlung solcher Zellen in 
Mausmelanomen beobachtet. Dies steht im Zusammenhang mit einer stark erhöhten Metastasenbildung 
im Melanom-Mausmodell. 
Zusammenfassend zeigen meine Resultate auf, dass die Proliferation und die Invasion von 
Melanomzellen gleichzeitig auftreten kann, was zu einem aggressiven Melanomtypus führt. 
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3. Introduction 
3.1 Definition and Epidemiology of Cutaneous Melanoma 
 
Cutaneous melanoma is the least common but the most deadly skin cancer type originating from neural-
crest derivative melanocytes during development, colonize mainly the skin and eye, a broad range of 
other tissues throughout the body (Mort et al. 2015).  In total, an estimated 76, 380 new cases of 
melanoma were diagnosed in 2016  (Rebecca L. Siegel et al. 2016). Over the past 3 decades, the number 
of people diagnosed with melanoma has increased sharply. Incidence rates differ among different 
populations, with the highest rates worldwide being reported in Australia and New Zealand, where the 
incidence rate reaches ~60 cases per 100,000 inhabitants per year (Figure 1A). In Europe, the rate is 
~20 events per 100,000 per year, whereas, in the United States, a rate of ~30 events per 100,000 per 
year has been reported. (Schadendorf et al. 2015). The rise in incidence rates yearly about is 2.5% in 
males and 3.9% females  (Raaijmakers et al. 2015). Incidence rates are higher in women than men 
before age 40, with a peak difference at age 20–24 (Liu et al. 2013). After the age 65, surprisingly, rates 
in men double those in women. (Rebecca L Siegel et al. 2016) (Figure 1B). Other than age and gender, 
a various number of risk factors are associated with melanoma susceptibility. For instance, cutaneous 
melanoma affects individuals with blue eyes, red hair and fair skin. In addition to the skin category, the 
high incidence rate of melanoma in white populations living closer to the equator obviously highlights 
the importance of sun exposure as a risk factor. Ultraviolet (UV) radiation has been predominantly 
linked to C>T nucleotide transition signature however, many melanomas lack this signature and have 
fewer point mutations. (Hayward et al. 2017) . Therefore, we still have to investigate the mechanisms 
involves in disease progression in order to further progress in melanoma epidemiology, prevention and 
targeted treatment globally. 
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A.                                                                                                      B. 
                 
 
Figure 1A. Incidence and mortality of cutaneous melanoma. The rates of incidence and mortality from 
melanoma per 100,000 inhabitants per year show differences between countries. Figure 1B. Melanoma incidence 
of male and female at different age. Incidence is greater among women than men between age 20 and age 40, 
but greater among men than women at ages greater than 50.  
 
3.2 Clinical features 
 
The clinicopathological classification system for melanoma was based on gross clinical and 
pathological features and includes four major subtypes – superficial spreading melanoma (SSM), 
nodular melanoma (NM), lentigo malignant melanoma (LMM) and acral lentiginous melanoma.  The 
first three were first described by Wallace Clark in 1967 (Hermanek et al. 1976).   Superficial spreading 
melanoma (SSM) is the most common subtype, accounting for approximately 70% of cases, occurs 
most often on the trunk, appears as an asymmetrical flat skin lesion with irregular pigmentation and 
border (Dummer et al. 2005) (Figure 2A). 
 
 
 
 
10 
 
Nodular melanoma (NM) accounts for about 15% of melanomas and often appears on the trunk, head, 
neck and tends to grow more rapidly in thickness (vertical growth phase) than in diameter. (Figure 2B) 
Instead of arising from an existing mole, it may appear in a spot where a lesion did not previously exist, 
therefore, the prognosis is often worse because it takes longer for the patients to be aware of the changes 
in the skin. NM is often pigmented; however, some NM lesions can be less pigmented or even non-
pigmented. (Figure 2B).  (Maverakis et al. 2015; Rustin 1990). Lentigo malignant melanoma (LMM) 
accounts for 13% of melanomas and correlates with chronic sun exposure in fair-skinned older 
individuals. The lesion is usually large (3-6 cm or greater), with a variable nodular area from 1mm to 
2cm in width (Wang et al. 2016) (Figure 2C). Acral lentiginous melanoma (ALM) occurs mainly on 
the nail beds, palms, and soles and is a relatively rare subtype (Bradford et al. 2009). Clinically, the 
lesion is characterized by a tan, brown-to-black, flat macule with color variations and irregular borders. 
(Figure 2D).  
 
There are also unusual variants such as amelanotic, desmoplastic, verrucous, polypoid melanoma, 
minimal-deviation melanoma or blue nevus, and account for %5 of the cases.  Among these, the more 
treacherous examples include the desmoplastic melanoma with prominent pigment synthesis and the 
malignant blue nevus. The inability to recognize unusual melanoma variants is because of the antigenic 
profiles of these tumors not commonly associated with a melanocytic histogenesis (Barnhill & Gupta 
2009). 
                             A.                          B.                        C.                        D. 
                              
Figure 2. Different primary melanoma types. Four major subtypes of primary melanoma presentation are 
shown. (Hoek website "Heterogenety in melanoma") 2A, Superficial spreading melanoma. 2B, Nodular 
melanoma. 2C, Lentigo maligna melanoma. 2D, Acral lentiginous melanoma. 
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3.2.1 The Clinical Presentation and Morphology 
 
The ABCDE criteria can be useful in early melanoma detection. The criteria include: A for asymmetry 
of lesions, B for border irregularity, C for colour variegation, D for diameter (greater than 5mm) and E 
for evolving (particularly focusing on changes to shape, size, symptoms (itching), surface (bleeding, 
papular or nodular formation) and pigmentation over time) (Abbasi et al. 2004). The criteria are not 
helpful to diagnose lesions with vertical growth involvement or amelanotic melanomas; thus, other 
methods such as histopathological examination are often used together for accurate diagnosis.  
3.3 Pathological features and staging 
3.3.1 Clark’s level of invasion and Breslow’s thickness  
 
Previously, very thin tumors were classified according to Clark’s level of invasion; however, the key 
features for the new staging system includes the thickness of the tumor, known as Breslow’s thickness. 
Clark’s level of invasion classification method measures the depth of invasion of a melanoma into the 
skin according to anatomic layer. In addition to the anatomic level, the cell proliferation rate (mitotic 
index) is also used for the prognosis (Hermanek et al. 1976).The Clark levels characterized by five 
levels. Level I is represented by the melanomas limited to the outermost layer of the epidermis, also 
called "melanoma in-situ." Level II is defined by the infiltration of the melanoma cells in to the dermis 
of the skin. This stage is progression from radial growth phase to vertical growth phase. Level III, IV 
considered by the invasion into the reticular dermis. Level V is marked by infiltration of melanoma 
cells into the fat layer of the skin beneath the dermis and infiltration into the third layer of the skin, the 
subcutaneous. (Hermanek et al. 1976).  Contrary to Clark levels , Breslow’s measures the tumor 
thickness in millimeters from the upper granular cell layer to the deepest point of the invasive tumor 
cell (Breslow 1970). 
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 3.3.3 TNM staging system 
 
The TNM classification of malignant tumors (TNM) staging system was defined by the American Joint 
Committee on Cancer (AJCC) and revised in 2011 based on the analysis of 17,600 patients in the AJCC 
Melanoma Staging Database. TNM classification describes the stage of a certain cancer  which 
originates from a primary tumor with alphanumeric codes. T stands for primary tumor, N for regional 
lymph nodes, and M for metastases. Stage 0 melanomas are non-invasive and still have the integrity of 
the epidermal basement membrane. Stage I (≤ 2 mm according to Breslow’s method) and stage II 
melanomas are only localized primary tumor and there is no sign tumor cell spread to lymph nodes or 
other parts of the body. Stage III is characterized by regional spread through lymphatic vessels and 
stage IV by distant metastasis. (Balch et al. 2009). The latest summary of TNM classification of 
cutaneous melanoma mentioned above in Table 1. 
Table 1. TNM Staging for melanoma revised in 2011. 
 
 
Stage Primary Tumour  
T
is
 In situ  
T1  ≤ 1,0 mm - a) without ulceration / b) with ulceration   
T2  1.01 – 2.0 mm a) without ulceration / b) with ulceration  
T3  2.01 – 4.0 mm a) without ulceration / b) with ulceration  
T4  > 4.0 mm a) without ulceration / b) with ulceration  
N  Regional Lymph nodes  
N1  One lymph node a) micrometastasis b) macrometastasis 
N2  2-3 lymph nodes a) micrometastasis
 
b) macrometastasis
 
c) in-transit metastases / 
satellite metastases without metastatic lymph nodes  
N3  ≥ 4 metastatic lymph nodes, matted lymph nodes or combinations of in-transit 
metastases / satellite(s) or ulcerated melanoma and metastatic lymph nodes  
M  Distant Metastases  
M1a  Distant skin, subcutaneous, or lymph node metastases (normal LDH)  
M1b  Lung metastases (normal LDH)  
M1c  All other visceral (normal LDH)  
or any distant metastases (elevated LDH)  
LDH = Lactate dehydrogenase  
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3.4 Pathogenesis of cutaneous melanoma  
 
The whole genome sequencing data available from the data portal of The Cancer Genome Atlas (TCGA) 
and the data portal of the International Cancer Genome Consortium (ICGC) for various cancers has 
proved that cancer types differ in their overall mutation rates, predominant mutation types and 
distribution of mutations along their genome (Lawrence et al. 2013). These mutations in cancer 
genomes are most likely due to the consequence of the intrinsic changes in infidelity of the DNA 
replication machinery, mutagen exposures, enzymatic modification of DNA, or defective DNA repair 
(Pfeifer 2010). In case of melanoma, UV induced mutagenic effect seems to have major contributor to 
the mutation rate. Large-scale melanoma exome data samples demonstrate a high base mutation rate in 
compared to many form of solid cancer (Hodis, Ian R. Watson, et al. 2012) (Figure 3A). 
 
A.  
 
 
Figure 3A. The prevalence of somatic mutations across human cancer types. The prevalence of somatic 
mutations was highly variable, ranging from about 0.001 per megabase (Mb) to more than 400 per Mb. Every dot 
represents each sample whereas the red horizontal lines are the median numbers of mutations in the respective 
cancer types. ALL, acute lymphoblastic leukaemia ; AML, acute myeloid leukaemia; CLL, chronic lymphocytic 
leukaemia.  
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3.4.1 Chronically sun damaged melanoma vs. non-sun damaged melanoma  
 
The most common types of melanoma are found on sun-exposed skin and be subtyped based on their 
cumulative levels of exposure to ultraviolet (UV) radiation. To a large extend, it can be also categorized 
by their anatomical origins and levels of sun exposure (chronically sun damaged CSD versus non-
chronically sun damaged non-CSD melanomas) (Shain & Bastian 2016). CSD melanomas often 
originate from the head, the neck and the dorsal surfaces of the distal extremities and shows macroscopic 
and microscopic signs of continuing exposure to UV radiation (Broekaert et al. 2010). Instead, non-
CSD melanomas typically affect the more irregularly sun-exposed areas such as the trunk and proximal 
extremities.  Furthermore, CSD melanomas have high mutation load mainly neurofibromin1 (NF1), 
NRAS, BRAF nonV600E or KIT mutations while non-CSD melanomas are associated with a moderate 
mutation burden and a predominance of BRAFV600E mutations (Bastian 2014; Viros et al. 2008).  
 
The high mutation rate of CSD melanomas are associated with UV induced DNA damage (Ikehata & 
Ono 2011). UV radiation frequently leads to DNA mutations such as the formation of pyrimidine dimers 
or deamination of cytosine into thymidine. These DNA mutations mostly induces G->T transversions 
and G->A transitions (Besaratinia & Pfeifer 2006). UV exposure generates highly mutagenic 
DNA photoproducts in which two adjacent pyrimidines are covalently linked to form cyclobutene 
pyrimidine dimers (CPD) or pyrimidine (6–4) primidone photoproducts (6–4PP). Furthermore, these 
unrepaired photoproducts can interfere with DNA replication and transcription throughout the genome 
can eventually give rise to mutations in coding regions of genes including oncogenes and tumor 
suppressor genes.  These alterations in the genome could promote benign lesion formation by allowing 
the clonal expansion of melanocytes carrying specific mutated genes.  
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3.4.2 Melanoma Progression 
 
Melanoma progression is a complex process. Primary tumor formation has classically been thought to 
use a linear model in which normal melanocytes progress through different precursor lesions and, 
ultimately, to melanoma. However, there are different melanoma types that can be linked to different 
precursor lesions. Each subtype of melanoma can evolve through different evolutionary routes, passing 
through (or sometimes skipping) various stages of transformation (Shain & Bastian 2016). For instance, 
almost 12% of melanomas can arise with no an identifiable cutaneous precursor lesion, suggesting that 
not all steps necessarily occur during progression of individual malignant melanomas (Damsky et al. 
2011) (Figure 4B). In contrast, the linear model for melanoma formation often suggests a linear path of 
progression from nevus to dysplastic nevi, to melanoma in situ, to invasive melanoma (Bandarchi et al. 
2010) (Figure 4A). After formation of identifiable primary tumor, melanoma cells are assumed to enter 
lymphatic vessels, reach to the proximal lymph node, and subsequently infiltrate systemic circulation. 
Once reaching the systemic circulation, cells must adhere to the microvasculature of a target organ, 
extravasate, and subsequently proliferate to form a clinically relevant metastasis (Figure 4B). For each 
step, the molecular and environmental mechanisms vary between different melanomas and different 
target organs to achieve the metastasis formation. In the linear model, progression of individual lesions 
is thought to be driven by the acquisition of several genetic/epigenetic changes. Therefore, fully 
developed melanoma metastasis harbor numerous changes in their genome. 
 
The classification of specific mutations can be based on the melanoma type still, the most recurrent 
somatic mutations in both  CSD and non-CSD melanomas affect genes in key signaling pathways that 
govern proliferation, growth and metabolism, resistance to apoptosis, cell cycle control and replicative 
lifespan (Hodis, Ian R. Watson, et al. 2012; Huang et al. 2013; Horn et al. 2013; Krauthammer et al. 
2012; Hayward et al. 2017). The presence of certain mutations in certain precursor lesions and the 
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association of these precursor lesions with specific types of melanoma help us to understand the order 
of sequential information for these pathways become disrupted, yet, it is partly understood. 
 
A.                                                                            B. 
 
 
Figure 3A. The morphological spectrum of melanocytic neoplasms. Top row: clinical images showing a free-
standing nevus, a dysplastic nevus, melanoma in situ and invasive melanoma. Second row: schematics illustrating 
the architectural features for each type of lesion Rows 3,4,5: photomicrographs illustrating the representative 
histopathological features of each type of lesion B. Schematic steps in melanoma metastasis. according to 
Damsky et al 2011. 
 
3.4.3. Significantly mutated genes in melanoma 
 
The latest complete melanoma genomes / exomes sequencing data from cutaneous, acral and mucosal 
subtypes of melanoma resolved novel signatures of mutagenesis inferable to UV (identified 228,987 
mutations, including both SNVs and indels across different types) (Tsao, Chin, L. a Garraway, et al. 
2012). UV signature mutations in melanoma found in many genes and mainly associated with a C>T 
nucleotide transition (Health et al. 2013; Brash 2015). However, many melanomas lack the UV 
signature and have very low number of point mutations. (Berger et al. 2012; Krauthammer et al. 2012). 
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Moreover, the number of affected genes in non-coding sequences were found in a similar extend to 
recurrent mutations in coding sequences. Nonetheless, researchers could have still categorized the 
subtype of cutaneous melanomas based on the significantly mutated genes such as BRAF, NRAS, NF1 
and TP53 subtypes. In case of acral melanoma BRAF, NRAS and NF1 were the predominant mutations 
found whereas in mucosal melanoma SF3B1 was additionally identified (Hayward et al. 2017; Shain & 
Bastian 2016). Remarkably, mutations affecting the TERT promoter were the most frequent of all; 
however, these mutations were functionally linked with telomere protection and lengthening but in turn 
they do not result in significant telomere lengthening. (Hayward et al. 2017). The previously described 
melanoma oncogenes and tumor suppressors BRAF, NRAS, CDKN2A, TP53, and PTEN, along with 
recently discovered mutated genes RAC1, MAP2K1, PPP6C, and ARID2 had potential roles in 
components of signaling pathways.  (Hodis, Ian R. Watson, et al. 2012; Krauthammer et al. 2012; Tsao, 
Chin, L. a Garraway, et al. 2012; Haass et al. 2014). Aside from these recently identified different 
mutations, cutaneous melanoma was classified into four molecular subtypes based on their main genetic 
driver: BRAF-mutant, NRAS-mutant, NF1-mutant, and triple wild-type tumors (Figure. 4A). 
 
 
 
Figure 4A. Main melanoma-driver genes that reach genome-wide significance according to background 
mutation-frequency estimation. Purple, metastatic melanoma; green, patients over 65 years old; red, mutations 
at recurrent positions; dark blue, inactivating mutations (nonsense, splice, indel); light blue, predicted harmful 
mutations. Brown and darker orange represent sun-exposed tumors and tumors of unknown origin, respectively.  
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3.4.3.1 BRAF Subtype 
 
The mitogen-activated protein kinase (MAPK) pathway is implicated in various cancers because of its 
role in the regulation of cell growth, survival, invasion. The MAPK signaling begins with the activation 
of the protein RAS by receptor tyrosine kinases. Activated RAS induces the membrane recruitment of 
various RAF proteins. Following recruitment, RAF proteins phosphorylates MEK, another key protein 
kinase, and phosphorylates ERK, which can directly and indirectly activate many transcription factors 
that are crucial for cell proliferation and survival. (Gaggioli et al. 2007; Santarpia et al. 2012; Knight & 
Irving 2014; Rauen 2013). In melanoma, activation of this pathway mostly occurs by the presence 
of BRAF hot-spot mutations (Davies et al. 2002a).  BRAF somatic missense mutations have been 
detected in 66% of malignant melanomas. These mutations were mainly found in the kinase domain, 
with a single substitution; V600E (Valine -> Glutamine) accounting for 80% of all such cases (Davies 
et al., 2002). Interestingly, 82% of benign nevi also present with BRAF mutations, yet it is not sufficient 
for malignant transformation (Dong et al. 2003; Omholt et al. 2003).  The appearance of BRAF 
mutations in early nevi indicates that the acquirement of activation of BRAF is a clonal, key driving 
event (Dong et al. 2003; Omholt et al. 2003). Also, there are other well-documented V600 amino acid 
residue substitutions: V600K (Valine->Lysine), and V600R (Valine->Arginine). The second most 
frequent BRAF mutation targeted the K601 residue. (Davies et al. 2002b)The patient samples harboring 
BRAF
 
V600E hot spot mutation are not having a common UV induced signature. In these samples, the 
transversion of T  A resulting of the substitution at distinct nucleotide that is different from UV-
induced pyrimidine dimer formation (Davies et al., 2002). It has been also shown that BRAF mutations 
arising on non-CSD melanomas are more common than CSD melanomas, acral melanomas and mucosal 
melanomas that the tissues are relatively unexposed to sunlight (Curtin et al. 2005; Chin 2003). Also, 
patients in the BRAF subtype were younger than patients in the other subtypes (Cancer Genome Atlas 
Network 2015).  
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3.4.3.2 RAS Subtype 
 
The second main subtype is defined by the presence of RAS hot-spot mutations mostly including NRAS 
Q61K/L/R or NRAS G121D.  13–25% of all malignant melanomas have been shown the presence of 
somatic mutations in NRAS locus (Ball et al. 1994; Curtin et al. 2005; van ’t Veer et al. 1989). 
Surprisingly, RAS mutations recurrent in congenital nevi and absent in acquired nevi (Roh et al. 2015). 
These mutations are missense mutations which lead to an amino acid substitution at positions 12, 13, 
or 61. The outcome of these mutations is constitutive activation of NRAS and subsequently activation 
of MAPK signaling pathways. NRAS mutations are more common in melanomas derived from CSD 
skin  (Hayward et al. 2017).  
 
3.4.3.3 NF1 Subtype 
 
The third most frequent mutation seen in MAPK signaling was NF1 protein, neurofibromin 1 that 
negatively regulates RAS proteins. NF1 is a GTPase-activating protein known to downregulate RAS 
activity through its intrinsic GTPase activity and loss of function of NF1 is an alternative way to activate 
the canonical MAPK signaling pathway (Sharma et al. 2013). NF1 mutations in melanoma typically 
occur on CSD skin or in older individuals, show a high mutation burden, and interestingly are wild-
type for BRAF and NRAS. (Cancer Genome Atlas Network 2015). As well, NF1 mutations characterize 
certain melanoma subtypes mainly desmoplastic melanoma (Maertens et al. 2013).  
 
3.4.3.4 Triple Wild-Type Subtype 
 
The triple wild type subtype defined by a lack of hot-spot BRAF, NRAS, or NF1 mutations and in these 
subtype, several known driver mutations for uveal melanoma such as GNAQ, KIT, CTNNB1 and 
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EZH2 were found. Strategies to target melanomas that are BRAF/NRAS/NF1-wild type have recognized 
even more indefinable to cure. The analysis of somatic copy-number alteration (CNA) among subtypes 
have demonstrated that the Triple-WT had significantly more copy-number alterations and was enriched 
for crucial amplifications targeting known oncogenes (Hayward et al. 2017). For instance, the 
oncogene KIT, PDGFRA and KDR (VEGFR2), were frequently co-amplified in these samples. Some of 
the BRAF/NRAS/NF1 wild type melanomas from patient data showed also amplification in crucial 
oncogenes such as cyclin D1 and CDK4 as well as MDM2 and TERT  (Hodis, Ian R. Watson, et al. 
2012).  
 
3.4.3.5 Genes involved in familial melanoma  
 
The family history of the melanoma is one of the most significant risk. It has been reported that those 
born in families with history of melanoma have a 30-70% increase in the chance to develop melanoma. 
Approximately 10% of melanoma cases report a first- or second-degree relative with melanoma  (Aoude 
et al. 2015). Even though familial melanoma accounts for only few percentage of all melanoma cases, 
it is very crucial to understand the genetic basis of the germline mutations for melanoma susceptibility 
in order to develop new methods for early detection. 
 
3.4.3.5.1 High penetrance genes 
 
Principally, there main melanoma predisposing genes have been discovered.  So far, CDKN2A is the 
main high-risk gene involved in melanoma susceptibility. Germline mutations in the coding region are 
observed in around 20%. (Aoude et al. 2015).  The locus encodes two following important cell cycle 
regulator proteins: inhibitor of cyclin-dependent kinase 4A ( p16 INK4A) and alternate reading frame  
(ARF p14ARF(p19 ARF in mice) (Serrano et al. 1996).  A second high-penetrance gene is cyclin-dependent 
kinase 4 (CDK4), even though only three families have been reported to harbour the mutation. (Zuo et 
al. 1996). These two proteins roles in the same cell-cycle regulatory pathway, namely that G1 to S phase 
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transition. The constitutive activation of CDK4 protein is oncogenic, since this kinase negatively 
regulates Retinoblastoma (Rb) by phosphorylation. Once phosphorylated, pRB disassociates from the 
transcription factor E2F1 and rescuing E2F1 from cytoplasm bound state letting it to shuffle into the 
nucleus and regulating genes that are essential for G1 to S phase transition (Duronio & Xiong 2013). In 
contrast, p16 is a tumor suppressor, is a CDK inhibitor, inhibits the kinase activity of CDK4 and 
subsequently, decelerates the cell cycle by prohibiting transition from G1 phase to S phase (Stone et al. 
1995; Nobori et al. 1994). Mutated p16Ink4a is no longer able to inhibit CDK4 mediated phosphorylation 
of the Rb and, resulting in the same effect, mutated CDK4 is unable to bind functional p16Ink4a. Similar 
to p16, p14ARF is a tumor suppressor protein but acts through a different pathway. ARF protein induces 
cell cycle arrest by stabilizing of p53 via HDM2 mediated ubiquitination (Pomerantz et al. 1998; Stott 
et al. 1998).  
 
3.4.3.5.1 Low penetrance genes 
 
A third susceptibility-gene, the melanocortin 1 receptor (MC1R), shows low penetrance so it confers 
lower risk (Kennedy et al. 2001).  MC1R gene determines individual’s skin phenotype by influencing 
the ratio of eumelanin to pheomelanin (Lin & Fisher 2007). Eumelanin does responsible for the brown 
to black color for the skin, eye and hair while pheomelanin accounts for yellow to red color that is less 
photoprotective. Thereby, pheomelanin variants are more prone to produce reactive oxygen species 
(ROS) and subsequent DNA damage (Lin & Fisher 2007; Wong & Rees 2005). Due to the shift from 
eumelanin to pheomelanin, carriers for MC1R variants have red hair, freckles, fair skin with reduced 
tanning ability. Pheomelanin increased type has diminished UV-light protection, and consequently, 
melanocytes with such MC1R variants are very sensitive to the DNA damaging effects of UV radiation 
(Scott et al. 2002).  
 
Recently, new genes involved in melanoma susceptibility have been identified; breast cancer 1 
(BRCA1), BRCA1-associated protein 1 (BAP1), and telomerase reverse transcriptase (TERT). (Potrony 
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et al. 2015). Analysis of these genes allow us to identify a larger number of high-risk individuals with 
a potential of developing familial. It is important that these individuals receive adequate management 
along with frequent dermatological examinations, genetic counselling and instrumental examinations 
aimed at the early identification of other tumors associated with cutaneous melanoma.  
 
The number, size and color of melanocytic nevi is related to frequency and amount of intermittent sun 
exposure and associated with an elevated risk of melanoma (Slominski et al. 2001; Gandini et al. 2005). 
Thus, clinicians use the ABCD (A) asymmetry, (B) vague border, (C) variegated pigmentation, (D) 
diameter exceeding 5 mm, (E) elevation score as a prediction rule to determine the risk for nevi to 
progress to developing melanoma.  
 
3.4.4 Molecular alterations in signal pathways of melanoma 
3.4.4.1 PTEN signaling  
 
Since its discovery, phosphatase and tensin homolog deleted in from chromosome ten (PTEN) known 
as an elusive tumor suppressor gene (Salmena et al. 2008). A broad variety of human cancers including 
melanoma harbour PTEN alterations such as loss of heterozygosity (LOH) and rearrangements of 
chromosome 10 (Aguissa-Touré & Li 2012). PTEN has both lipid and protein phosphatase functions 
that are essential for regulating the cruical pro-survival PI3K/AKT signaling pathway  (Worby & Dixon 
2014). PTEN negatively regulates the phosphatidylinositol-3-kinase (PI3K) pathway by 
dephosphorylating PIP3, subsequently decreases the intracellular PtdIns (3,4,5)P3 levels and 
downstream AKT activity (Cantley 2002) (Figure 5). AKT activation promotes the downregulation of 
antiapoptotic proteins and the upregulation of proapoptotic signals resulting in controlled cellular 
survival, growth and proliferation. Another consequence of AKT activation is cell-cycle arrest at G1/S 
that is mediated by the upregulation of the cyclin-dependent kinase inhibitor p27. (Shanmugasundaram 
et al. 2013). Thus, loss of PTEN regulation often results in reduced proliferative and apoptotic control 
(Aguissa-Touré & Li 2012). 
 
 
 
23 
 
PTEN has also phosphatase function which targets proteins and protein phosphatase activity of PTEN 
is apparently less essential for tumorigenesis. For instance, dephosphorylation of focal adhesion kinase 
(FAK) has been shown to inhibit adhesion and migration properties of human cancer cells (Tamura et 
al. 1999). Additionally, PTEN is thought to intersect and inhibit growth factor-stimulated mitogen 
activated-protein kinase (MAPK) signaling by dephosphorylating certain adapter proteins, resulting in 
reduced MEK activity (Carracedo & Pandolfi 2008). For instance, previously it has been shown that 
activation of MAPK via growth signals such as epidermal growth factor (EGF) and platelet-derived 
growth factor (PDGF) can be blocked by exogenous PTEN expression in human glioblastoma cells 
(Furnari et al. 1997; Furnari et al. 1998).  
 
As a summary, the loss of PTEN lipid and protein phosphatase activity one of the crucial event for 
tumor biology and may result in aberrant cell growth and surveillance from apoptosis, as well as cell 
migration. In melanoma, PTEN loss has been mostly observed as a later event, even though a level-
dependent loss of PTEN protein has been implicated in early stages of tumorigenesis (Wu et al. 2003). 
In addition, PTEN alterations strongly correlate with BRAFV600E hot spot mutation, even though 
analysis of human cell lines shows that inactivation of PTEN and  RAS activation are not coincident in 
melanoma (Goel et al. 2006). In melanoma, loss of PTEN on chromosome 10 has been observed in 30-
60% of sporadic cases and  PTEN mutations or deletions have been found in 30-40% of established cell 
lines (Shain & Bastian 2016; Goel et al. 2006). 
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Figure 5. Signaling pathways in melanoma. MAPK signaling promotes cell growth and survival. RAS family 
members are activated by RTKs and signal through effector proteins, including RAF kinases, PI3K, and Ral-
GEFs.  
 
3.4.5.2 The RAS/RAF/MEK/ERK pathway 
 
The mitogen-activated protein kinase (MAPK) pathway is implicated in many type of cancers and 
activated in 80% of all cutaneous melanomas. Activation of this pathway occurs via growth factor 
stimulation, activating mutations in signaling components or other type of growth-factor receptors 
(Gray-Schopfer et al. 2007). The signal is transduced by specific receptor tyrosine kinases, cytokines, 
and G-protein-coupled receptors (Lu et al. 2006). There are 3 different RAS proteins in human including 
HRAS, KRAS, NRAS. Upon RAS activation, the kinase activity of target RAF proteins (ARAF, BRAF 
and CRAF in humans) is induced via complex formation. (Roberts & Der 2007; Leevers et al. 1994). 
This activated complex leads to the phosphorylation of mitogen-activated protein kinases (MAPK also 
known as ERK) via activation of MEK proteins (MEK1 and MEK2) (Arthur & Ley 2013). 
Subsequently, the signal is transduced in to the nucleus in order to regulate the expression of several 
genes involved in cell proliferation, differentiation and survival by phosphorylating nuclear 
transcription factors such as ETS, ELK-1, MYC or indirectly by targeting intracellular signaling 
molecules. It also effects the post-translational phosphorylation of apoptotic regulatory molecules like 
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BAD, BIM, MCL-1, caspase 9 and BCL-2. The pathway is constitutively activated by growth factors 
such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), vascular endothelial 
growth factor (VEGF), stem cell factor (SCF), fibroblast growth factor (FGF), hepatocyte growth factor 
(HGF), and glial-cell-derived neurotrophic factor (GDNF) (Santarpia et al. 2012). 
 
In melanoma, constitutive activation of MAPK pathway leads to induce proliferation, survival, 
invasion, and angiogenesis. The abovementioned somatic BRAF mutations occur 80% of cases in early 
melanomagenesis. (Davies et al. 2002a) Yet, most nevi do not progress into malignant melanoma 
suggesting that BRAF mutation may be required but not sufficient to induce malignant transformation. 
Activated BRAF has been shown to result in a senescence-like state and further melanoma progression 
requires the presence or absence of additional genetic events such as loss of tumor suppressor. 
Furthermore, mutations in NRAS oncogene that is approximately 15%–30% of cases, cause senescence 
phenotype when expressed in normal melanocytes (Tsao, Chin, L. a Garraway, et al. 2012; Dong et al. 
2003). In addition to NRAS and BRAF some other MAPK pathway components frequently also are 
mutated in human melanoma cell lines and melanoma samples such as in MAP3K5 and MAP3K9. 
(Stark et al. 2011). MAPK signaling pathway is currently good target for anticancer therapy respecting 
to its high frequency of mutations. Nevertheless, identification of perfect pathway component to 
therapeutically target for maximal clinical benefit to melanoma patients remains a challenge.  
 
3.4.5.3 WNT Signaling 
 
WNT pathway signals via three distinct pathways; the canonical B-catenin pathway, the Ca2+/PKC 
pathway and the planar cell polarity pathway and mediates cell proliferation, differentiation, polarity 
and cell fate determination. (Webster et al. 2015). WNT signaling is very crucial in development 
however, aberrant signaling has been implicated in many human cancers. The various Wnt family of 
proteins, with the main receptors and co-receptors, emphasise the complexity and diversity of WNT 
signaling. WNT signaling is initiated by frizzled family of receptors, which are G-protein-coupled 
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receptors. Besides to Frizzleds, WNT signaling also requires multiple co-receptors, such as ROR1 and 
ROR2, LRP5/6 and Ryk (Wu & Nusse 2002; Webster et al. 2015). The well-known  WNT canonical 
signaling pathway involves the intermediate signaling β-catenin protein and is termed the canonical 
pathway (Nelson 2004). Non-canonical WNT signaling includes both the Ca2+/PKC pathway and the 
planar cell polarity pathway mediated via JNK signaling. (Komiya & Habas 2008; Habas & Dawid 
2005).  
 
Canonical WNT signaling promotes pigment-cell formation by medial crest cells, thereby crucial for 
the development of melanocytes from their neural crest precursors (Dorsky et al., 1998). The regulation 
of melanocyte development is via the activation of microphthalmia-associated transcription factor 
(MITF) that is appeared to be the master regulator of melanocyte identity. Given the role in 
development, it is likely that the elevated level of WNT signaling makes a considerable contribution to 
the transformed phenotype of melanoma cells. For instance, there are lots of evidences for the activation 
of the canonical β-catenin pathway through the immune-histochemical detection of nuclear β-catenin 
in a subset of primary melanomas suggests a role for this pathway in melanoma development (Rimm et 
al., 1999, (Rubinfeld 1997; Huber & Weis 2001; Arozarena et al. 2011) Mutations of B-catenin have 
been described in melanoma cell lines and various primary melanoma showed 4% of oncogenic 
mutations. Furthermore, active WNT/b-catenin signaling was observed in 30% of melanoma 
tumors.(Chien et al. 2009).  Constitutive expression of β-catenin is enough to promote tumor 
progression in transgenic mouse models, although it is well known that β-catenin is critical in the early 
stages of melanocyte transformation and melanoma genesis, its significance in metastases and prognosis 
is still a matter of debate. (Delmas et al. 2007).  
 
3.4.5.4 TGF-β Signaling and deciphering the molecular components 
 
The members of the transforming growth factor-β (TGF-β) super-family are multifunctional cytokines 
controlling various cellular processes, including cell proliferation, differentiation, apoptosis, fate 
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determination as well as embryo patterning during development (Shi & Massagué 2003; Siegel & 
Massagué 2003). The TGF-β super-family have more than 40 human cytokine members including the 
TGF-βs, activins, NODAL, bone morphogenetic proteins (BMPs), growth and differentiation factors 
(GDFs) and anti-Müllerian hormone (AMH) (Siegel & Massagué 2003). TGF-β superfamily ligands 
signal through two transmembrane serine/threonine kinase receptors, a type II ligand binding receptor 
and a type I signal transducing receptor. The functional receptor at the cell surface desires both type I 
and type 2 heterodimer formation (Wrana et al. 1992).  
 
A.                                                                                  B. 
 
 
Figure 6A, Canonical TGF-β signaling. The active form of the TGF-β ligand is a dimer of two molecules held 
together by hydrophobic interactions and a disulfide bond. This dimer induces the formation at the cell surface 
the active receptor hetero-tetramers. The type II receptors phosphorylate the type I receptors; the type I receptors 
are then enabled to phosphorylate cytoplasmic R-Smads (in case of TGF-β type I receptors phosphorylates 
Smad2/3) which then complex with the co-Smad, Smad4 and translocate to the nucleus to bind DNA at specific 
Smad binding elements (SBE). This pathway is inhibited by Smad7.  7B, Table showing the specificity of TGF-
β superfamily ligand-receptor interactions in human. 
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Upon ligand binding to a type II receptor at the cell surface, a type I receptor is recruited and 
phosphorylated by the type II receptor. Phosphorylation leads to the activation of its receptor kinase 
domain. The activated type I receptor recruits and phosphorylates receptor-regulated Smads (R-
SMADs). Phosphorylated R-SMADs bind to the co-mediator SMAD (Co-SMAD) and translocate to 
the nucleus where the heteromeric complex interacts with other transcriptional factors (TF) including 
co-activators and co-repressors (Silvestri et al. 2010) (Figure 6A). 
 
3.4.5.4.1 SMAD Proteins  
 
Specific TGF-β superfamily ligands recruits different combinations of type I and type II receptors, as 
indicated Figure 6B (Massagué 1998). In human, there are seven type I receptors, namely activin 
receptor like kinases (ALK1-7) and five various type II receptors (TGFβR-II, ActR-IIA, ActR-IIB, 
BMPR-II, and AMHR-II) are responsible for the signal transmission. (Schmierer & Hill 2007) 
Receptors have cysteine-rich extracellular domain, a single-pass transmembrane domain and an 
intracellular kinase domain. SMAD2 and SMAD3 are type of R-SMADs that are effectors of TGF-β, 
activin or NODAL signaling and are phosphorylated by ALK4, ALK5 and ALK7. (Schmierer & Hill 
2007)On the contrary, SMAD1, SMAD5 and SMAD8 are involved in BMP signaling and they are 
phosphorylated by ALK1, ALK2, ALK3 and ALK6.(Massagué & Gomis 2006).  The receptor-mediated 
phosphorylation of the R-SMADs occurs at their carboxyl terminus on two serine residues in an S-M-
S or S-V-S motif. The recognition of different R-Smads by the various type I receptor kinases is highly 
specific and the phosphorylation promotes binding to SMAD4, subsequently accumulation in the 
nucleus  (Hata & Chen 2016). 
 
SMAD proteins are defined by two conserved MAD-homology (MH) domains, namely MH1 and MH2. 
Among R-SMADs, these domains share more than 90% homology at the amino acid level, however an 
additional 30 amino acid were discovered in MH1 domain of Smad2 (Figure 7). This insertions inhibits 
its ability to bind DNA (Dennler et al. 1999). The MH1 domain is responsible for binding to specific 
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CAGA sequence, known as Smad-binding DNA element (SBE)  (Jonk et al. 1998). The ability to bind 
the accurate promoter is also dependent on the co-activators and co-repressors at the transcriptional 
level (Massague & Gomis 2006). In contrast, the MH2 domain does not bind DNA and instead is having 
interactions to provide specificity and selectivity. (Imoto et al. 2003; Wang et al. 2009). The TGF-β 
signals is mediated by the direct association of extreme carboxyl terminus of the MH2 domain with the 
TGFβ receptor complex. The R-SMADs are then directly phosphorylated by the type I TGFβ receptor 
kinase on the last two serines of a conserved SSXS motif located at the extreme carboxyl terminus of 
the MH2 domain.   
 
 
Figure 7. Domain structure of Smads. MH1 domain of Smad2 contains an additional 30 amino acids denoted 
by dark green box. Smad3 contains a trans-activation (TA) in its linker region. Smad4 contains Nucleus Export 
Signal (NES) in its linker region. Smad2,3 and Smad4 contains a Nucleus Localization Signal (NLS) in their MH1 
domain. Smad7 lacks MH1 domain. 
 
Another type of SMAD proteins is composed of the inhibitory SMADs (I-SMADs), SMAD6 and 
SMAD7. Remarkably, SMAD7 inhibits signaling by both TGF-β and BMPs mediated signals whereas 
SMAD6 preferentially inhibits BMP signaling (Hayashi et al. 1997; Kretzschmar et al. 1997). The MH1 
domain of I-SMADs have amino-N domains and they are quite dissimilar to R-SMADs with respect to 
amino acid sequence. (Dennler et al. 1999)However, they conserve the extreme carboxyl-terminal MH2 
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domains (Silvestri et al. 2010) The N domains are essential for specific inhibition of TGF-β signaling 
by Smad7, whereas the MH2 domains are involved in the inhibition of TGF-β signals through 
interaction with type I receptors. SMAD7 negatively regulates the TGF-β signaling at the different 
levels; including competing with R-SMADs for receptor binding, recruiting E3-ubiquitin ligases 
(SMAD ubiquitination regulatory factor 1 and 2 (Smurf1 and Smurf2) leading to type I receptor 
degradation or recruiting factors for type I receptor dephosphorylation (Yan et al. 2009a).  
3.5 TGF-β Superfamily ligands and cancer 
3.5.1 TGF-β isoforms 
 
TGF- β family consists of three members (TGF- β1-3) that show high similarity and homology even 
though they are encoded by three distinct genes, they share ~80% amino acid sequence homology. 
(Fimmel et al. 1999). The TGF-β cytokine is synthesized as a pre-TGF-β protein containing the C-
terminal and N-terminal domains.  After the cleavage by furin-like endoproteinase, the pro-polypeptide 
called the latent-associated peptide (LAP), at which , the LAP dimer remains associated with the mature 
TGF-β dimer (Shi et al. 2011). This complex, known as the small latent complex, is secreted. However, 
this complex often associates through the LAP to one of four latent TGF-β binding proteins (LTBP) to 
be secreted as a large latent complex. Release of the mature TGF-β molecule is induced by cleavage of 
the LAP by various proteases. (Schiller et al. 2004; Javelaud & Mauviel 2004). TGF-β then mediates 
its effect through the heteromeric receptor complex consisting of TβR-II and ALK5.  
 
In cancer, TGF-B isoforms have many crucial functions; as a tumor suppressor, TGF-β has control on 
proliferation, apoptosis, and instead, as a tumor promoter, it plays a crucial role in angiogenesis, 
migration and invasion, immune surveillance (Massagué 2008). Additionally, many clinical studies 
have been demonstrated that the levels of TGF-B ligands are increased in patients from different type 
of cancers such as colon cancer, breast cancer, melanoma (Friedman et al. 1995; Chod et al. 2008; 
Krasagakis et al. 1993). In early-stage tumors, levels of TGF-β are positively associated with a favorable 
prognosis, while in late-stage tumors, they are positively associated with poor prognosis (Padua & 
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Massagué 2009). Thereby, it is well accepted that TGF-β pathway has dual role in cancer (Inman, 2011; 
Principe et al., 2014).  
 
The recent paradigm for the role of TGF-β in tumorigenesis is that accumulation of genetic alterations 
in the signaling switches it is role from tumor-suppressive to tumor-promoting actions (Jakowlew 2006; 
Neuzillet et al. 2015). Indeed, tumor progression requires shutting down the tumor-suppressive arm of 
the signaling, which can be achieved by two mechanisms. The first one is inactivating the signaling by 
either through mutation or through allelic loss of heterozygosity (LOH), of the core components: the 
receptors or the SMAD transcription factors (Padua & Massagué 2009). Inactivating mutations in the 
gene for TβR-II are found in colon and gastric cancers, as well as in glioma (Chung et al., 1996; Izumoto 
et al., 1997; Ku et al., 2007; Markowitz et al., 1995). Inactivating mutations in the gene encoding ALK5 
are less frequent but are found in breast, colorectal, ovarian, head and neck, and pancreatic cancers, and 
T-cell lymphoma (Chen et al., 1998; Chen et al., 2001a; Chen et al., 2001b; Goggins et al., 1998; Ku et 
al., 2007; Schiemann et al., 1999). Mutations in Smad2 are relatively rare and are limited to a few cases 
in colon, lung, gastric, and head and neck cancers (Han et al., 2004; Qiu et al., 2007; Riggins et al., 
1996; Tsang et al., 2002; Uchida et al., 1996). Smad4 mutations occur in approximately half of cases of 
pancreatic cancer and are also detected at a lesser frequency in other carcinomas including colon 
carcinomas (Hahn et al., 1996; Schutte et al., 1996). Loss of Smad4 also correlates with cancer 
progression and metastasis (Losi et al., 2007; Luttges et al., 2001; Xu et al., 2000). These genetic 
inactivation’s of core components of the TGF-β pathway result in removal of tumor-suppressive 
activities. Nevertheless, this is not the case of many cancers such as breast, prostate cancers, melanomas, 
and gliomas that often retain functional TGF-β signaling. These tumors can benefit from the remaining 
TGF-β activities promoting tumor progression and metastasis.  
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3.5.2 TGF-β’s tumor suppressor role 
 
TGF-β is a ubiquitous cytokine that is well described for its ability to inhibit epithelial cell proliferation 
via regulating several crucial genes involved in controlling cell cycle progression. In early-stage tumors, 
the TGF-β pathway promotes cell cycle arrest and apoptosis (Dooley & ten Dijke 2012; Yin et al. 2012; 
Jakowlew 2006). In case of cell cycle progression, activated target genes are the CDK inhibitors 
including p21Cip1, p27Kip1 and p15Ink4b (Hannon & Beach 1994; Kamesaki et al. 1998; Datto et al. 1995; 
Scandura et al. 2004). p15Ink4b interacts and inactivates CDK4 and CDK6, and thus prevents progression 
through the G1/S cell cycle controlling point (Hannon & Beach 1994).  Activation of p15Ink4b is further 
enhanced by the downregulation of c-Myc. TGF-β signaling represses the expression of c-Myc and 
therefore inhibits its recruitment to the p15Ink4b promoter, relieving c-Myc induced repression of p15Ink4b 
(Seoane et al., 2001; Staller et al., 2001).  In addition to inhibiting proliferation, TGF-β may also induce 
apoptosis. (Schuster & Krieglstein 2002). For example, TGF-β has been shown to regulate the 
expression of pro- and anti-apoptotic molecules, including p53, Bad, Bax, Bik, Bcl-2 and Bcl-XL 
(Heldin et al. 2009; Jakowlew 2006) 
 
3.5.3 TGF-β’s tumor promoter role 
Malfunction of TGF-β signaling can result in many pathological changes, among which epithelial-
mesenchymal transition (EMT) is a well-studied process that endows cancer cells with increased 
aggressiveness. EMT refers to the reprogramming of epithelial cells to a mesenchymal cell. The TGF-
β pathway regulates, acting alone or in cooperation with other signaling pathways, these transcription 
factors, which confers TGFβ a potent inducer of EMT (Yang et al. 2004; Heldin et al. 2012) The pro-
oncogenic role for TGF-β signaling was well defined in breast cancer.  It has been demonstrated that 
presence of a dominant negative TβR-II together with an initiating oncogenic lesion leads to increase 
the frequency of malignant transformation of breast epithelial cells and increase the aggressiveness of 
a low-grade breast carcinoma (Tang et al., 2003). Conversely, the loss of TGF-β signaling did not affect 
primary tumorigenesis, but suppressed metastasis in a high-grade breast carcinoma (Tang et al., 2003). 
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The SMAD proteins are also implicated in breast cancer metastasis. The expression of dominant 
negative SMAD3 or expression of a mutant form of the TGF-β type I receptor, in human mammary 
epithelial cells, significantly diminished their ability to colonize the lungs. (Theohari et al. 2012). 
Moreover, overexpression of the inhibitory Smad7 impaired mammary carcinoma cell invasion. (Yu et 
al. 2016).  The major role in promoting breast cancer metastasis comprises other ways of acting such 
as at the tumor stroma level. Remodeling  the surrounding extracellular matrix (ECM), through 
stimulation of matrix metalloproteinase (MMP) expression and modulation of the plasminogen 
activation system, resulting in TGFβ-mediated matrix degradation and, consequently, an increasing 
release of stored TGFβ from the ECM that acts as a TGFβ reservoir  Indeed, in many types of cancer, 
increased production of TGF-β correlates with higher tumor grade and stimulates angiogenesis, 
contributes to myofibroblast differentiation and causes local and systemic immunosuppression, further 
contributing to tumor progression and metastasis.  
 
1.5.3 TGF-β’s in melanoma 
 
In normal melanocytes, TGF-β1 act as an inhibitor of proliferation. Normal melanocytes and melanoma 
cells express and secrete high quantities of the three TGF-β isoforms, TGF-β1, TGF-β2 and TGF-β3 
and these ligands are able to induce their own expression via positive amplification loop. While 
melanomas express TGF-β constitutively, melanocytes require exogenous growth factor stimulation for 
TGF-β production (Rodeck et al., 1994). Normal melanocytes are growth-inhibited by TGF-β; however 
melanoma cells show resistance to its antiproliferative activity. As previously mentioned, alterations in 
the components of the pathway in melanoma are very rare, therefore various mechanisms have been 
suggested to understand the escape from a cytostatic response to TGF-β. For instance, phosphorylation 
of the SMAD2 and SMAD3 linker regions was detected to be high in both melanoma cell lines and 
melanoma samples. Such event has previously been associated with the weaker SMAD2/3 activity, 
leading to downregulation of TGF-β- responsive genes such as p21, p15 and c-MYC.  
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Activation of TGF-β pathway in melanoma cell lines has been well demonstrated. The basal 
phosphorylation level of SMAD3 is detectable in vitro in melanoma cells, demonstrating a constitutive 
activation of the TGF-β receptors. It has also been shown that phosphorylation of SMAD2 in melanoma 
cells is associated with SMAD2 phosphorylation in neighboring keratinocytes, indicating that TGF-β 
pathway could affect the tumor microenvironment. Furthermore, TGF-β blockade by means of either a 
neutralizing pan-TGF-β antibody or SMAD7 overexpression inhibited basal SMAD -dependent 
transcriptional activity in melanoma cells.  
 
In human melanocytic lesions, higher levels of nuclear phosphorylated SMAD2 are found in benign 
melanocytic nevi, melanomas in situ, and primary invasive melanomas, suggesting that hyperactivated 
TGF-β/SMAD pathway can be related to melanoma progression in the skin, and may be a critical switch 
from radial to vertical growth during melanoma progression 
  
The tumor promoter of TGF-β has been demonstrated via strongly induce plasminogen activator 
inhibitor-1 (PAI-1) synthesis, leading to a significant decrease in tissue-type plasminogen activator 
(tPA) and urokinase-type plasminogen activator (uPA) secretion, which in turn led to tumor growth 
inhibition in a mouse melanoma model (Ramont et al., 2003). On the other hand, metastasis has also 
been shown to be facilitated by TGF-β’s induction of matrix metalloproteinase-9 (MMP9) and β1 and 
β3 integrins, downregulation of E-cadherin expression (Janji et al., 1999), as well as by enhancement 
of melanoma cell adhesion to the endothelium (Teti et al., 1997). Also, TGF-β stimulation of 
neighboring stromal fibroblasts which translated into an increased production and deposition of 
extracellular matrix proteins was shown to increase survival and metastasis of melanoma in mice 
(Berking et al., 2001). 
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3.5.2 Activin 
Activin is a TGF-β-family cytokine, was initially found with its ability to stimulate follicle-stimulating 
hormone release by the anterior pituitary (Ling et al., 1986). Activin has known to regulate a variety of 
events, including cell proliferation, differentiation, apoptosis, homeostasis, immune response, wound 
healing and different endocrine functions (reviewed in Chen et al., 2006. In human, the two most 
common subunits are βa and βb expressed and, once subunits are linked, they either form the two 
homodimers activin A and activin B or the heterodimer activin AB. These ligands signal through the 
type II activin receptors (ActRII and ActRIIB) and the type I receptors ALK2, ALK4, and ALK7, with 
ALK4 being the most important signal transducing receptor which in turn phosphorylates R-SMADs; 
SMAD2/SMAD3 (Shi et al. 2011).  
 
3.5.3 Activins in melanoma 
The role of activin in cancer is not very clear however, mutations in several genes involved in the activin 
signaling pathway have been characterized. For instance, somatic ACVR1B gene mutations have been 
found in pancreatic carcinoma and Smad2 as well as Smad4 are mutated in colorectal and pancreatic 
carcinomas. Also, Activin A ligand is overexpressed in human skin cancer, as well as other tumors, and 
transgenic expression of activin A in mouse skin enhanced tumorigenesis through effects specifically 
on the local immune response, by increasing the number of TReg cells. Regarding tumor cell 
autonomous response, studies have been linked to activins effects on tumor cell growth.  Increased 
activity of the pathway either by Cripto silencing or FLRG silencing inhibits human breast cancer cell 
growth. It has been shown that activin enhances the expression of p15Ink4b, reduces the expression of 
cyclin A and phosphorylate pRb in breast cancer (Burdette et al., 2005). The inhibition of proliferation 
by activin has been supported by other studies with human tumors including cells from prostate and 
pituitary gland (reviewed in Chen et al., 2006). Nevertheless, activin has been shown to increase 
proliferation of ovarian cancer cell lines highlighting, the actions of activin in tumor growth are highly 
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context-dependent. (Steller et al., 2005), Alternatively, the pro-angiogenic role of activin is thought to 
be more crucial in cancer. Activin function as an inhibitor of angiogenesis. Overexpression of the activin 
gene in neuroblastoma cells has been shown to reduce the proliferation rate of primary tumors with 
reduced vascularity in a xenograft mouse model (Panopoulou et al., 2005). Recent work from Daniel 
B. Constam and co-workers provided an evidence with respect to the angiogenic role. They have shown 
that activin-A secretion stimulates melanoma cell dedifferentiation and tumor vascularization by 
functional blood vessels, and it increases primary and metastatic tumor burden. The differential 
expression of the βB subunit in high- and low-metastatic melanoma cell lines suggested that activin may 
have a role in metastasis in melanoma (Hashimoto et al., 1996). The group of Stove et al. have been 
shown that melanocytes but not melanoma cell lines were growth inhibited by activin. These melanoma 
cell lines further show high expression levels of activin inhibitory molecule follistatin suggesting a 
model for an effective way to escape its growth inhibitory action Stove et al., 2004).  
 
3.5.4. NODAL 
 
NODAL is a developmental morphogen rarely detected in normal adult tissues and known to play a role 
in stem cell maintenance, regulation of organ development and positioning (Pereira et al. 2012; )The 
signaling typically initiates after binding to a receptor complex consisting of the EGF-like protein 
Cripto-1 and type I (ALK4/7) and type II (ActRIIB) Activin-like kinase receptor.(Kenney et al. 2004) 
A prominent role of NODAL signaling in the developing mouse embryo and in HESCs is to drive 
pluripotency and self-renewal (Galvin et al. 2010; Park 2011). NODAL signaling pathway has been 
considered as a very attractive target for tumor therapy since it is not expressed in adult tissues, and the 
CRIPTO 1 capable of potentiating this signaling pathway by acting as a coreceptor, is only expressed 
at low levels, but both are often reactivated in tumors (Lawrence et al. 2011; Friedman et al. 1995) 
. 
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3.5.5 NODAL signaling in melanoma 
 
The role in cancer for NODAL has recently been demonstrated in pancreatic cancer, where NODAL is 
essential to drive cancer stem cell renewal (Donahue & Dawson 2011).  In a mouse model of pancreatic 
cancer, pharmacological inhibition of NODAL signaling in the cancer stem cells abolished their self-
renewal capacity. In melanoma, the expression pattern of the NODAL protein and transcript in a panel 
of human normal, neoplastic and stem cell types have been screened (Donahue & Dawson 2011). This 
study revealed that, similar to human ES cells, melanoma cells express NODAL while in normal 
melanocytes its expression is not detected (Strizzi et al. 2012). In addition to being expressed in 
melanoma cells, same group identified that NODAL expression positively correlates with melanoma 
tumor progression toward a metastatic phenotype. NODAL is highly expressed by aggressive 
metastatic melanoma cell lines such as C8161, WM278 and 1205Lu, while expression is weakly 
detected or absent in non- metastatic melanoma cells. (Topczewska et al. 2006; Fang et al. 2013). Also, 
IHC analysis has demonstrated that NODAL protein is rarely observed in poorly invasive RGP 
melanomas however, expression is increased in up to 60% of cases with invasive VGP melanomas and 
melanoma metastases 
Besides the role as a useful biomarker for melanoma progression, Nodal has also been demonstrated to 
be important for maintaining melanoma cell plasticity, invasiveness and tumorigenicity. The lab of 
Hendrix with functional studies have been proved that inhibition of NODAL abrogated melanoma 
growth, decreased expression of VE-cadherin, and prevented the formation of vasculogenic networks 
or channels-like structures, phenomenon named as vasculogenic mimicry (VM). Based upon these 
observations, other groups reasoned that expression of NODAL might be spatially associated with the 
VM in human melanoma. (Postovit et al. 2008; Topczewska et al. 2006). Humanized murine model for 
the study of VM in melanomas, Nodal mRNA expression was associated with tumor cells that in 
adjacent sections formed CD144-positive, CD31- negative channels. (McAllister et al. 2010). 
Additionally, increased staining intensity was focally associated with CD144-positive anastomosing 
channels. These data suggest that melanoma cells selectively express Nodal mRNA in a channeled 
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pattern typical of VM, and further support the key role of this ligand in melanoma progression. The role 
of Nodal in melanoma has been correlated with stem cell-like patterns of protein expression Hendrix 
and co-workers have been shown that expression of the Nodal coreceptor, Cripto-1, in a subset of slow-
growing, sphere-forming malignant melanoma cells (Strizzi et al. 2012; Topczewska et al. 2006). These 
cells also expressed increased levels of stem cell markers Oct4 and Nanog. In this regard, Hendrix has 
speculated that Nodal expression in melanoma cells may correlate with a more potentially stem-like 
subpopulation of malignant cells within the tumor. 
 
3.5.6. BMPs 
 
BMPs are so called because they were originally discovered by inducing bone and cartilage formation. 
These proteins are the largest ligand subfamily in the TGF-ß superfamily of ligands dedicated to 
different functions. The BMP ligand family is composed of, following ligands: Bmp2, Bmp3, Bmp4, 
Bmp5, Bmp6, Bmp7, Bmp8a, Bmp8b, Gdf2 (also named Bmp9), Bmp10, Gdf11 (also named Bmp11), 
Gdf7 (also named Bmp12), Gdf5 (also named Bmp14), Gdf6 (also named Bmp13) and Bmp15. The 
role of BMP signaling in carcinogenesis is quite context dependent, i.e., both pro-tumor and anti-tumor 
effects have been described (Liu et al. 1996; Kretzschmar et al. 1997). The most prominent indication 
that BMP signaling pathways contribute to tumorigenesis comes from genetic studies of familial cancer 
syndromes. Mutation of BMPR-IA (Alk3) is genetically responsible for familial juvenile polyposis. 
(Nishanian & Waldman 2004). Other germ line mutations in BMPRIA (Alk3) have also been identified 
in a subset of families with Cowden syndrome, an inherited breast cancer syndrome (Zhou et al. 2001). 
In addition, it has been shown that various sporadic human cancers also exhibit aberrations in BMP 
ligand expressions. Overexpression of BMP2, 4, and 5 is observed in premalignant and malignant 
lesions of oral epithelium (Jin et al. 2001). In prostate cancer, BMP6 is found in metastatic lesions and 
its expression correlates with increased recurrence and decreased survival. Also, high levels of BMP7 
were also detected in bone metastasis of prostate cancer. (Li & Koeneman 2009). Previous observations 
demonstrated that prostate carcinoma cells produce increasing amounts of BMPs as the disease progress 
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and the upregulation of BMP7 expression in metastatic cells is a critical component of the mechanism 
of developing osteoblastic lesions.(Li & Koeneman 2009) BMP7 is also upregulated in breast 
carcinoma and paradoxically its expression correlates with differentiation markers.  
 
In colorectal carcinoma, BMP2 acts as a tumor suppressor and its expression is lost during the disease 
progression. Similarly, BMP2 is downregulated in breast cancer and BMP2 treatment inhibits growth 
of breast carcinoma cells in vitro. (Chapellier et al. 2015; Rosen 2009). BMP2 also exhibits 
antiproliferative and proapoptotic effects on myeloma, gastric, prostate, and ovarian. Indeed, BMP 
signaling has also been functionally associated to stimulate cell migration, tumor invasiveness, 
angiogenesis, and matrix remodeling. Specifically, BMP2, while growth-inhibitory in A549 lung 
carcinoma cells, enhances migration and invasion in an autocrine manner. In prostate cancer cells, 
BMP7 activates the VEGF promoter through an autocrine loop and upregulation of VEGF in turn, 
promotes angiogenesis and osteoblastic activity at bone metastatic sites. Despite the progress achieved 
revealing the functional significance of BMP pathways in carcinogenesis little is known about BMP 
signaling in melanoma.  
 
3.5.7 BMPs in melanoma 
 
Multiple BMPs are upregulated during melanoma progression.  Upregulation of BMP 2, 6, 7 and 8 was 
found in melanoma cell lines compared to normal melanocytes (Rothhammer et al. 2005). At the 
transcript level screening of  BMPs expression among isogenic cell lines isolated from the same patient 
at different disease stages has been shown that in particular, BMP7 correlates with tumor aggressiveness 
(Hsu et al. 2005). Forced expression of BMP7 resulted in growth inhibition of different melanocytic 
cells, however invasive melanoma cell lines show %50 less growth inhibition response compared 
control cell lines (Wang & Hirschberg 2003). It has been suggested that advanced melanoma cells 
escape from growth inhibition by BMP7 through upregulation of BMP antagonist, noggin.  
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3.5.8 Negative growth regulators and tumorigenesis 
 
The paradigm that melanoma cells produce negative growth regulators, such as TGF-β, has been 
discussed by many scientists over the years. It is only until recently that advances in understanding 
molecular aspects of the TGF-β receptors, their signal transduction pathways, and their effects on gene 
modulation enabled the formulation of a widely accepted model, in which TGF-β plays a dual role in 
tumorigenesis. In early stages of tumor progression, TGF-β functions as a tumor suppressor critical for 
maintaining homeostatic control of growth. As the melanoma cells progress toward a more aggressive 
phenotype, they develop resistance to the growth-inhibitory and pro-apoptotic effects of TGF-β, while 
secreting ever-increasing quantities of TGF-β. In response to elevated TGF-β levels, the tumor cells 
become more migratory and invasive. Taken together, it is conceivable that like TGF-β, BMP7 may 
exert both anti-tumor and pro-tumor effects in melanoma progression that are dose- and context 
dependent. Despite the increased production of endogenous BMP7, advanced melanoma cells are 
resistant to growth inhibition through disruption of BMP7 signaling by noggin upregulation and high 
levels of BMP7 in turn promote metastasis through angiogenesis and matrix remodeling. 
 
3.6 Phenotype Switching model 
 
The classic Clark model depicts linear transformation of melanocytes to malignant melanoma and 
subsequent development of invasion and metastasis (Takata et al. 2010). To form metastases, tumor 
cells first have to acquire an invasive potential, which allows the cells to emigrate from the primary 
tumor, to reach the blood stream, and eventually to colonize distant organs. This process of invasiveness 
involves tightly regulated switch process of different cellular phenotypes. In melanoma, a very similar 
phenomenon, i.e. the dynamic and reversible transition from a proliferative to an invasive state, has also 
been described and is known as “phenotype switching”.  The expression analysis of various human 
melanoma cell lines identified these phenotypes with very diverse gene expression profiles correlated 
with distinct behaviors in vitro. The highly proliferative, poorly invasive phenotype is characterized by 
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melanocytic differentiation markers whereas the highly invasive phenotype group is characterized by 
the expression of many genes whose expression is very similar to the EMT program during development 
(Vandamme & Berx 2014a). 
 
The EMT program functions during the process of melanocytes to emerge from the neural crest cells 
and has shown to have a crucial role in acquisition of metastatic properties during the vertical growth 
phase of melanoma (Bennett 2008). Recently, EMT markers has been shown to have a fluctuating 
expression profile in various type of cancers as well as melanoma during the disease progression. The 
traditional transcription factors (EMT-TFs) during induction of EMT in many cancers act a repressor 
of E- Cadherin and include SNAIL1/2, ZEB1/2, and TWISTs. (Caramel et al. 2013; Thiery et al. 2009). 
However, among others, ZEB1, TWIST1 and ZEB2 found to have different levels of expression in 
normal melanocytes and different phenotypic states of melanoma cells. Analysis of normal epidermal 
melanocytes from a melanoma patient revealed low ZEB1 and high ZEB2 expression, whereas the 
melanoma cells at deep sites of the primary tumor from the same patient showed high expression of 
ZEB1 and low expression of ZEB2 (Caramel et al. 2013).  The loss of ZEB2 in melanocytes resulted in 
dedifferentiation, and in melanoma cells resulted in increased ZEB1 expression and contributed to 
invasive behavior and metastasis (Denecker et al. 2014).  Furthermore, immunohistochemistry analysis 
of a cohort of patient samples revealed high expression of ZEB1 and TWIST1, with low expression of 
ZEB2 corresponded with significantly reduced metastasis-free survival (Caramel et al. 2013). In the 
same study, SNAIL2 and ZEB2 transcription factors are found to be expressed in normal melanocytes 
and behave as tumor-suppressor proteins by activating an MITF driven melanocyte differentiation 
program whereas ZEB1 and TWIST1 repress this differentiation process and possess oncogenic 
properties. Consistent with the literature on the role of MITF in phenotype switching, these studies also 
proved that MITF was regulated by the switch in ZEB expression and downregulation of MITF lead to 
an invasive phenotype (Keith S Hoek & Goding 2010; Vandamme & Berx 2014b). In addition to switch 
in ZEB expression, several groups have proposed loss of E-cadherin/gain of N-cadherin (cadherin 
switch) was a major determinant of phenotype switching in melanoma and believed to responsible for 
melanoma cell detachment from the epidermis(Alonso et al. 2007). Only few studies correlated the 
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expression levels of cadherins with clinical outcome in patients with melanoma. These studies suggest 
that the interchange between epithelial-like and mesenchymal-like phenotypes is context dependent in 
different types of melanoma such as uveal melanoma, but the ability to switch phenotype in various 
types of melanoma has been implicated in conferring a higher risk of death due to metastasis. (Keith S 
Hoek & Goding 2010; Onken et al. 2006)  
3.6.1 MITF and AXL 
 
MITF (microphthalmia-associated transcription factor) characterizes a melanocytic lineage-specific 
transcription by regulating the expression of melanocyte differentiation genes such as tyrosinase, silver 
homologue (GP100) and melanoma-associated antigen recognized by T cells-1 (MART-1 or 
MELANA)  (Levy et al. 2006). Also, it is known as the master regulator of melanocyte development as 
well as the crucial regulator for melanoma formation. MITF expression is heterogeneous and present in 
the majority of melanomas (Tsao, Chin, L. A. Garraway, et al. 2012). Alterations in MITF expression 
have been found in a relatively small subset of melanomas. However, MITF is still considered an 
oncogene after Garraway and co-workers detected MITF amplification in 10% of primary cutaneous 
and 15-20% of metastatic melanomas (Garraway et al. 2005). Furthermore, it has been shown that 
elevated MITF levels in synergy with activated MAPK signaling promote melanoma growth. On the 
other hand, distant metastasis showed low levels or absence of MITF expression. (Nazarian et al. 2010; 
Hodis, Ian R. Watson, et al. 2012; De Snoo & Hayward 2005). Thus, expression of MITF has been 
suggested to be used as a marker to distinguish melanoma cells in the proliferative or invasive state.  
 
In addition to these observations, MITF was initially found to be essential in both the survival of 
melanoblasts migrating from the neural crest and in the differentiation process of the retinal pigment 
epithelium. (Opdecamp et al. 1997). Next, its role was implicated in the expression of differentiation 
genes important for the melanosome function as well as in the differentiation-associated cell cycle arrest 
via upregulation of the p16 and p21 cyclin-dependent kinase inhibitors (Garraway et al. 2005). 
However, other observations have proved its requirement for the inhibition of invasion and promotion 
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of proliferation via suppression of p27 protein together with upregulation of DIA1 protein (Carreira et 
al. 2006).  
 
These studies allow Garraway and co-workers to draw a rheostat model for MITF function in 
melanoma. According to this model, low MITF is a hallmark of stem-like cells, whereas high MITF is 
characteristic for proliferative or differentiated cells depending on the expression levels. Alternatively, 
it also has been shown that transient MITF depletion generates a G1 arrested, high p27, invasive type 
cell that is predicted to have stem-like properties while longer-term MITF depletion in melanoma leads 
to senescence (Strub et al. 2011) (Figure 8). Thus, understanding the properties of MITF-low cells and 
MITF-high cells is still a key issue that could have important implications for melanoma therapy.  
 
Other groups working on the role of MITF in melanoma have extended the rheostat model in association 
with resistance to MAPK inhibitors. For instance, increased MITF expression causes resistance to ERK 
inhibition and is consistent with other reports showing that MITF is sufficient to render melanoma cells 
resistant to MEK or ERK inhibitor-induced cell death  (Smith et al. 2013; Huang et al. 2013).  In 
contrast, sensitive melanomas also exhibited high activity of MITF and high expression levels of 
downstream differentiation markers like TYRP1, MLANA, and PMEL.  However, knock down of MITF 
expression in these sensitive cell lines induced a phenotypic transition towards resistance (Wellbrock 
& Marais 2005).  
 
Another main finding in mechanism for melanoma resistance is that the expression of MITF is 
commonly deregulated. Both MITF-high and MITF-low resistant tumors were found in vivo.  During 
treatment with a MAPK pathway inhibitor, up to 75% of melanomas expressed increased MITF 
expression. However, only around 25% of high MITF melanomas progressed further. (Smith et al. 
2016). Recent works have clarify that the high expression of MITF could also contribute to resistance 
(Konieczkowski et al. 2014; Tirosh et al. 2016; Smith et al. 2013) . It is not very clear why MITF 
expression can be upregulated in resistant melanoma cells but some studies have demonstrated that the 
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upregulated expression levels of the MITF target genes such as BCL2A1 and PGC1α are important for 
resistance to MAPK pathway inhibition. (R. Haq et al. 2013; Rizwan Haq et al. 2013)  
 
Analysis of MITF-low subset of melanoma cells lacking melanocyte differentiation antigens have 
shown to express high levels of receptor tyrosine-kinases such as AXL (Sensi et al. 2011). Smith and 
co-workers demonstrated that almost 50% of melanoma tumors that have progressed after MAPK 
pathway inhibition have decreased MITF expression. Moreover, these cells show more invasive 
phenotype than the MITF-high subset of resistant cells. (Smith et al. 2016). Previously, microarray 
analysis of several BRAF and NRAS mutated melanoma cell lines revealed that MITF and AXL belong 
to two gene expression patterns association with two distinct phenotype (Hoek, Schlegel, et al. 2008). 
Melanoma cells with the AXL signature were also found to be less responsive to a wide range of 
inhibitors and identified as a novel mechanism for acquired resistance (Müller et al. 2014; Aplin 2011; 
Konieczkowski et al. 2014). Additionally, both in primary and acquired resistance, MITF levels 
inversely correlated most frequently with the expression of AXL. (Müller et al. 2014).  Same group has 
proved that low MITF/AXL ratio predicts early resistance to targeted therapy and MITF-low/AXL-
high/drug-resistance phenotype is common among mutant BRAF and NRAS melanoma cell lines. 
These observations revealed that MITF low and AXL high gene expression program correlates with 
MAPK inhibitor resistance in melanoma patients However, the cause of upregulation of AXL 
expression in melanoma cell lines is not fully understood. Not only for melanoma but also for other 
type of cancers AXL is a marker for resistance to various targeted therapies (Garraway et al. 2005; Chen 
et al. 2008; Wu et al. 2014). It is not implicated as an oncogenic driver itself, but AXL is often 
overexpressed in acute myeloid leukaemia (Estey & Döhner 2006). Not only for melanoma but also for 
other type of cancers AXL is a marker for resistance to various targeted therapies (Garraway et al. 2005; 
Chen et al. 2008; Wu et al. 2014). It is not implicated as an oncogenic driver itself, but AXL is often 
overexpressed in acute myeloid leukaemia (Estey & Döhner 2006). It is a member of the TYRO3, AXL, 
and MERTK family of receptor tyrosine kinases (Graham et al. 2014). 
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Figure 8.  High MITF level is associated with differentiation and intermediate level with proliferation. MITF 
regulates distinct functions in melanocytic cells at different levels of expression Melanoma cells may switch from 
a quiescent dedifferentiated (‘stem-like’) phenotype MITF-low to a proliferative phenotype MITF intermediate 
and finally to a differentiated, again cell cycle arrested phenotype MITF-high (adapted from Carreira et al., 2006)  
 
It is a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases (Graham et al. 
2014). The majority of AXL signaling occurs in a ligand dependent manner mediated by GAS6 and 
activating mutations within the AXL kinase domain are rarely found in cancer (The Cancer Genome 
Atlas, TCGA). AXL signaling can be activated by GAS6 in an autocrine or paracrine manner and 
clinically, GAS6 expression in tumor specimens has been shown to be an prognostic factor in urothelial, 
ovarian, lung adenocarcinoma, gastric cancer, and glioblastoma (Wu et al. 2014). Aside from these 
observations, single-cell RNA sequencing by Tirosch and co-workers have allowed for the 
identification of gene expression programs that are associated with rare drug-resistant populations 
within human melanoma tumors (Tirosh et al. 2016). Although the distinction between 
AXLhigh/MITFlow vs. AXLlow/MITFhigh phenotypes was used to classify melanomas at the bulk tumor 
level (Müller et al. 2014), single cell RNA sequencing of human melanoma samples has recently led to 
the identification of a fraction of double-positive AXLhigh/MITFhigh cells the function of which remains 
to be elucidated (Tirosh et al. 2016).  
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4. Approaches to investigating the roles of TGF-β signaling in melanoma 
 
During melanoma progression, malignant cells become resistant to the anti-proliferative effect of TGF-
β and the growth factor even promotes tumor aggressiveness at the later stages. Up to now, this 
knowledge has been gained with in vitro experiments. To address the role of TGF-β signaling in 
melanoma development in an in vivo model, we took the advantage of the murine Tyr::NRasQ61K   
INK4a-/- melanoma model mice which develops congenital nevi and subsequently primary tumors in 6 
months. We clarified the significance of TGF-β signaling for the initiation and progression of melanoma 
by manipulating the canonical TGF-β pathway in the melanocytic lineage of Tyr::N-RasQ61KINK4a-/- 
mice. We conditionally ablated key players the TGF-β pathway – either TGF-βRII or SMAD4 to fell 
TGF-β signaling or the main negative regulator SMAD7 to preserve an active signaling cascade. To 
supplement our in vivo findings, we will conduct in vitro assays on cell cultures also established from 
patient derived human melanoma cells.  
 
According to our results, we have evidence that in this mouse model, melanoma arises from the bulge 
region of the hair follicle. Thus, it is likely that upon N-Ras activation MSCs escape the inhibitory effect 
of TGF-β and become malignant. We aimed to conditionally ablate TGFβ-RII and SMAD4 in the 
melanocytic lineage of tumor developing mice at early and late time points. At the time point of tumor 
initiation lack of TGF-β signaling might support tumor formation, but at later stages, when melanoma 
cells become TGF-β dependent, TGFβ-RII ablation might prevent further tumor development and 
metastasis. To complement the studies, we will also conditionally ablate Smad7, an inhibitory key 
player in the TGF-β pathway (Moustakas and Heldin, 2009). This allows us investigating, whether 
constantly active TGF-β signaling is sufficient to prevent melanoma initiation. With these studies, we 
intend to gain knowledge about the in vivo function of TGF-β signaling in melanoma initiation and 
progression. 
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5. My Contribution to the projects 
In the course of my doctorate, I contributed to several projects in Prof. Lukas Sommer Lab; First year, 
I helped my supervisor Dr. Daniel Zingg with respect to experiments. These results have been accepted 
for publication and gave a new insight about the novel role of epigenetic modifier EZH2 in melanoma 
initiation and progression in the cancer field.  
• The epigenetic modifier EZH2 controls melanoma growth and metastasis through 
silencing of distinct tumour suppressors, Daniel Zingg,1 Julien Debbache,1 Simon Schaefer 
Eylul Tuncer,1 Phil F. Cheng, Yudong Zhang,1 Raquel Calçada,1 Jessica Haeusel,1 Mitchell 
P. Levesque,2 Kwok-Kin Wong,3 Reinhard Dummer,2 and Lukas Sommer1. Nat 
Communication 2015 
• EZH2-mediated primary cilium deconstruction drives metastatic melanoma formation 
Daniel Zingg,1 Ana T. Antunes,1 Simon. M. Schaefer,1 Julien Debbache,1 Phil F. Cheng,2 Eylul 
Tuncer,1 Yudong Zhang,1 Raquel Calçada,1 Jessica Haeusel,1 Mitchell P. Levesque,2 Kwok-
Kin Wong,3 Reinhard Dummer,2 and Lukas Sommer1 Under Revision Cancer Cell 2017 
The project deciphering the role of TGF-β Signaling in melanoma formation and progression was 
started by Dr. Daniel Zingg. He established Smad7lox/lox and TgFBrII lox/lox melanoma prone mice. 
have analyzed the phenotypes and gained more experience with transgenic murine melanoma models. 
(The data for TGFBRII mice is not shown due to the absence of phenotype). In the following years, I 
have established the Smad4 lox/lox colony in melanoma prone background. I conducted the majority 
of in vivo and in vitro experiments and analyzed most of the data. The results are illustrated in my Phd. 
thesis and recently accepted for revision in Journal Clinical investigations. 
• SMAD signaling promotes melanoma metastasis independently of phenotype switching  
Eylül Tuncer1, Daniel Zingg1, Sandra Varum1, Phil Cheng2, Sandra N. Freiberger2, Chu-Xia 
Deng3, Ingo Kleiter4, Mitchell P. Levesque2, Reinhard Dummer2, and Lukas Sommer1 Under 
Revision 2017 JCI 
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6. Results 
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6.1 Abstract 
 
Malignant progression of melanoma is thought to require the dynamic shifting of neoplastic cells 
between proliferative and invasive phenotypes. Contrary to this conventional “phenotype switching” 
model, we now show that augmented SMAD-dependent signaling in melanoma leads to emergence of 
malignant cells simultaneously displaying proliferative and invasive properties. Specifically, 
conditional deletion of Smad4, which abrogates canonical SMAD signaling, prevented tumor initiation, 
proliferation and metastasis formation in vivo, pointing to the requirement of both pro-proliferative and 
pro-invasive TGF-β superfamily factors for metastatic melanoma formation. Ligand screening 
identified BMP7 to promote melanoma cell proliferation even in the presence of pro-invasive TGF-β  
factors. However, an invasive phenotype was induced in melanoma cells upon inactivation of the 
inhibitory SMAD factor SMAD7, surprisingly without counteracting melanoma cell proliferation. 
Consequently, conditional Smad7 deletion in vivo sustained melanoma growth and at the same time 
promoted massive metastasis formation. Together with clinical data analysis, our findings indicate that 
modulation of SMAD7 levels triggers malignant transformation of melanoma by overcoming 
phenotype switching.  
 
6.1 Introduction 
 
Despite recent progress in therapy, melanoma is still by far the deadliest skin cancer, with a five-year 
survival rate of only 15% to 20% (Rebecca L Siegel et al. 2016). It is thought that the aggressiveness 
of the disease is largely due to an intrinsic plasticity of melanoma cells, allowing the dynamic and 
reversible switching from a high proliferative/low invasive to a low proliferative/high invasive state 
(Goding 2011; Cheli et al. 2011).This so-called “phenotype switching” has been functionally associated 
with metastasis formation and therapy resistance (Schlegel et al. 2015; Hoek, Eichhoff, et al. 2008; 
Hölzel & Tüting 2016). At the transcriptional level, the phenotype switching model has been linked to 
a shift between a transcriptional program governed by high expression of the microphthalmia associated 
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transcription factor (MITF), a melanoma lineage-survival oncogene, and a transcriptional program 
associated with high expression of the receptor tyrosine kinase AXL, a marker for resistance to various 
targeted therapies (Garraway et al. 2005; Chen et al. 2008; Wu et al. 2014). In contrast to proliferative 
melanoma cells characterized by high MITF expression, MITFlow cells with high invasive properties 
were shown to be linked to G1 cell cycle arrest (Carreira et al. 2006). However, while the distinction 
between AXLhigh/MITFlow vs. AXLlow/MITFhigh phenotypes was used to classify melanomas at the bulk 
tumor level (Müller et al. 2014), single cell RNA sequencing of human melanoma samples has recently 
led to the identification of a fraction of double-positive AXLhigh/MITFhigh cells the function of which 
remains to be elucidated (Tirosh et al. 2016).  
 
Phenotype switching has also been linked to tumor progression in several epithelial tumors (Yao et al. 
2010; Thomson et al. 2008). In those cases, a reversible epithelial-to-mesenchymal transition (EMT) 
promotes invasiveness and stem cell-like features in cancer cells (Valastyan & Weinberg 2011), which 
is driven by a network of embryonic EMT-inducing transcription factors (EMT-TFs) of the SNAIL, 
TWIST, ZEB, and bHLH/E47 protein families (Lamouille et al. 2014). Although melanoma is not an 
epithelial tumor, an EMT-like process can be observed in cell culture and has been associated with 
metastatic spread of the disease (Vandamme & Berx 2014b). In particular, activation of the MAPK 
pathway by oncogenic BRAF or NRAS promotes a switch from SNAIL2/ZEB2 expression to 
expression of TWIST1 and ZEB1, which enhance invasiveness of melanoma cells (Caramel et al. 2013). 
 
One of the major candidate pathways for driving reversible phenotype switching is SMAD-dependent 
TGF-β superfamily signaling, which controls EMT in many cancers (Javelaud et al. 2008; Massagué 
2012). Sustained expression of EMT-TFs in breast cancer cells is directly regulated by autocrine TGF-
β signaling (Gregory et al. 2011). In melanoma, different TGF-β isoforms, NODAL as well as different 
BMP ligands were shown to be expressed by tumor cells and to promote invasiveness in cell culture or 
in organotypic human skin cultures (Fang et al. 2013; Hoek, Eichhoff, et al. 2008; Rothhammer et al. 
2007; Schlegel et al. 2015; Topczewska et al. 2006). In support of this, attenuation of TGF-β signaling 
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by overexpression of SMAD7, an inhibitory SMAD protein (Yan et al. 2009b), or by treatment with a 
small molecule inhibitor, reduced bone metastasis formation by cells injected into the cardiovascular 
system in immunocompromised mice (Javelaud et al. 2007; Mohammad et al. 2011).  
 
However, other studies reported that melanoma cells exhibit partial resistance to the anti-proliferative 
activity of TGF-β family factors (Rodeck et al. 1999). Moreover, TGF-β dependent SMAD signaling 
and transcription was not restricted to invasive cells, but also observed in proliferative human melanoma 
cells (Rodeck et al. 1999). Likewise, in human tissue samples, nuclear pSMAD2/3 which mediates 
canonical TGF-β signaling was detected at all stages of the disease, including in benign hyperplastic 
lesions, cutaneous primary melanoma, as well as invasive melanoma (Lo & Witte 2008). Finally, 
inhibition of SMAD2/3 signaling by SMAD7 overexpression not only affected the invasiveness of 
melanoma cells, but also reduced their capacity to grow in vitro and upon transplantation into 
immunocompromized mice (Javelaud et al. 2007).  
 
The combined data suggest that SMAD-mediated signaling may exert various functions in melanoma, 
which are likely influenced by the cellular context and the TGF-β superfamily ligands the tumor cells 
are exposed to (Massagué 2012). Therefore, in an attempt to mimic the tumor microenvironment with 
respect to TGF-β-dependent SMAD signaling, we treated melanoma cells with various combinations 
of TGF-β family factors and addressed the relevance of overall TGF-β/SMAD signaling in melanoma 
in vivo by means of a genetic mouse model, in which tumors emerge spontaneously within an 
undisturbed 3D environment. Accordingly, we searched for factors modulating the proliferative and 
invasive capacities of melanoma cells and revealed SMAD7 to control transcriptional programs 
associated with concomitant MITFhigh/AXLhigh expression and increased macrometastasis formation. 
These experiments identify integrated SMAD signaling as a key driver of melanoma initiation, growth, 
and metastatic progression, pointing to a new therapeutic vulnerability in melanoma.  
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6.1.1 Conditional Smad4 deletion in a genetic mouse model of melanoma prevents 
tumorigenesis by reducing tumor cell proliferation 
 
To investigate the function of integrated TGF-β superfamily signaling in melanoma we used a 
genetically engineered mouse model in which spontaneous melanoma formation is induced by 
expression of Tyr::NrasQ61K on an Ink4a-deficient background (Ackermann et al. 2005). Downstream 
of TGF-β superfamily signaling, the receptor-associated SMAD (R-SMAD) proteins SMAD2/3 and 
SMAD1/5/8 are activated by TGF-β/ACTIVIN/NODAL or BMP signals, respectively (Goumans et al. 
2003; Liu et al. 1996). Activated R-SMADs interact with the common partner SMAD4, which is 
essential for all canonical transcriptional responses (Schmierer & Hill 2007). To generate conditional 
Smad4-deleted melanocytes in our murine melanoma model, we crossed Tyr::CreERT2 Smad4lox/lox 
R26R::LacZ Tyr::NrasQ61K Ink4a−/− with Smad4lox/lox R26R::LacZ Ink4a−/− mice (Figure 1A). To 
achieve inducible Cre-dependent recombination and thus loss of Smad4 expression, mice were injected 
intraperitoneally with tamoxifen (TM) at 1 month of age for 5 consecutive days, followed by their 
analysis at given time points after tumor formation in control mice (Figure 1B). Recombination 
efficiency was 66 ± 6%, as assessed by counting the percentage of cells with R26R::LacZ-mediated β-
galactosidase expression among Pax3-positive melanocytic cells in hyperplastic lesions 2 months after 
TM injection. Depletion of Smad4 at a stage before appearance of cutaneous melanoma in control mice 
resulted in a marked decrease of hyperplastic dermal lesions (Figure 1C). While hair follicles were 
mostly associated with ectopic pigmentation in Tyr::NrasQ61K Ink4a−/− mice (76 ± 5% hair follicles with 
ectopic pigmentation), Smad4 ablation inverted this phenotype towards a pigmentation pattern typical 
for wild-type mice (13 ± 3% hair follicles with ectopic pigmentation) (Figure 1D). Cells positive for 
the melanocytic marker Pax3 in hyperplasia of Smad4-ablated animals were also positive for β-
Galactosidase, suggesting that Smad4 is not essential for the survival of the melanocytic lineage (Figure 
1, E and F). Importantly, loss of Smad4 was also associated with a significant decrease in the number 
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of recombined skin melanomas (Ø ≥ 2mm), which readily emerged in control mice after approximately 
5 months of age (Figure 1, G and H). Consistent with the decreased skin tumor load, Smad4 conditional 
knock out (cKO) mice displayed strongly reduced numbers of metastatic lung nodules as compared to 
control animals (Figure 1I). Consequently, melanoma-specific survival was highly increased in Smad4 
cKO mice (Figure 1J). 
 
 
 
 
Figure 1 Conditional Smad4 deletion in a genetic mouse model of melanoma prevents tumorigenesis (A) 
Schematic of the melanoma mouse model used in this study, which harbors NrasQ61K, Ink4a−/−, Tyr::CreERT2 
and R26R Cre-reporter alleles. (B) Experimental strategy used to analyze early loss of Smad4 in Tyr::NrasQ61 
Ink4a−/− Tyr::CreERT2 R26R::LacZ mice.   
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Figure 1. Continues Conditional Smad4 deletion in a genetic mouse model of melanoma prevents 
tumorigenesis (C) Representative hematoxylin and eosin staining of trunk skin sections of control and cKO mice 
at day of sacrifice showing dermal hyperpigmentation. (D) Quantification of the percentage of hair follicles 
exhibiting ectopic pigmentation in control and cKO mice (n = 350 hair follicles quantified from six different mice 
for each genotype). (E) Immunofluorescent staining for Pax3 (control) and Pax3/β-Gal (cKO) on back skin 
sections at 6 months to quantify extent of dermal hyperplasia. Open arrowheads indicate Pax3-positive, white 
arrowheads Pax3/β-Gal double-positive cells. (F) Quantification of the percentage of dermal Pax3 cells between 
hair follicles. (n= 300 hair follicles from six different mice for each genotype.  
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Figure 1. Continues Conditional Smad4 deletion in a genetic mouse model of melanoma prevents 
tumorigenesis (G) Macroscopic pictures of a control and a Smad4 cKO littermate at 6 months post Smad4 
ablation. (H) Quantification of recombined primary tumor numbers per control and cKO mice at the day of 
sacrifice (n=10). (I) Quantification of lung macro-metastases counts at day of sacrifice using macroscopic pictures 
and staining on sections (n=12). (J) Kaplan–Meier curves comparing melanoma-specific survival of control and 
Smad4 cKO animals (n=12 (cKO), n=12 (control)). Data represented as a mean of three independent experiments 
± SEM. p<0.001***. P values calculated with unpaired Student’s t-test (D, F, H) and (I), log-rank Mantel–Cox 
test (J). HF, hair follicle; Epi, Epidermis; TM, tamoxifen. Scale Bars, 50μm (E), 500μm (C), 500μm (G) 
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6.1.2 Loss of Smad4 leads to decreased proliferation in established skin tumors 
 
Our findings reveal a requirement for Smad4 in melanoma initiation. To address the cellular mechanism 
mediated by Smad4-dependent signaling, we conditionally deleted Smad4 by TM treatment at a stage 
when skin melanoma had already appeared in Tyr::NrasQ61K Ink4a-/- Tyr::CreERT2 Smad4lox/lox 
R26R::LacZ mice (Figure 2A). No obvious phenotypic and cellular differences were observed between 
heterozygous Smad4lox/wt and Smad4wt/wt mice on a melanoma-driving genetic background. Hence, 
Tyr::NrasQ61K Ink4-/- Tyr::CreERT2 Smad4lox/wt R26R::LacZ animals were used as control animals for 
further analysis. High recombination efficiency was apparent at the day of sacrifice (Figure 2B). While 
apoptosis in recombined melanoma cells was generally low in Smad4 cKO mice and comparable to 
levels seen in control melanoma tissue, labeling of β-galactosidase-positive recombined cells with the 
proliferation marker Ki67 demonstrated significantly reduced proliferation in Smad4 cKO melanoma 
cells in vivo as compared to control melanoma cells (Figure 2, C-E). Indeed, whereas recombined 
control tumors harbored 44 ± 5% Ki67 / β-galactosidase double-positive cells, this number was reduced 
to 13 ± 2% in Smad4 cKO mice upon TM-induced Cre-mediated recombination (Figure 2D). We next 
ascertained if the altered proliferation rate observed in vivo was due to changes in melanoma cell cycle 
progression. For this purpose, we performed RNA interference-mediated silencing (siRNA) of SMAD4 
in human melanoma cells (Figure 2, F and G). Of note, the percentage of cells in G1/G0 phase in 
siSmad4-transfected cultures was increased relative to the siControl-transfected cells, indicating that 
downregulation of Smad4 expression suppressed cell cycle progression by promoting a G1/G0 cell 
cycle arrest. Thus, Smad4-mediated signaling is required not only for the formation, but also for the 
proliferation of melanoma lesions, indicating that it promotes rather than counteracts tumor growth in 
vivo. Strikingly, even when Smad4 was depleted in our mouse model only once skin tumors were 
established, tumor-bearing mice exhibited significantly increased survival (Figure 2, H and I), revealing 
a crucial requirement for canonical TGF-β superfamily signaling for melanoma progression. 
 
 
 
 
57 
 
 
 
Figure 2. Loss of Smad4 leads to decreased proliferation in established skin tumors (A) Experimental strategy 
used to analyze the deletion of Smad4 in already established skin melanomas. Tyr::NrasQ61K Ink4-/- 
Tyr::CreERT2 Smad4lox/wt R26R::LacZ and Tyr::NrasQ61KInk4-/- Smad4lox/lox R26R::LacZ used as control 
animals. (B) Recombination efficiency was calculated by counting percentage of β-gal/Pax3-double positive cells 
on primary tumor sections (n=6, cKO and control). (C) Representative immunofluorescent co-staining of Ki67 
with β-Galactosidase on skin melanoma sections 72 hours after conditional deletion of Smad4. White arrowheads 
indicate Ki67/β-Gal double-positive cells, open arrowheads Ki67-negative/β-Gal-positive cells. (D) 
Quantification of Ki67 and β-Gal double-positive cells in control and cKO mice (n=4). (E) Quantification of 
apoptotic cells by IHC for activated caspase-3 on skin sections of control and cKO mice (n=4). (F) Reverse 
transcription qPCR (RT–qPCR) for expression of SMAD4 in M010817 and 501Mel after siRNA treatment. (G) 
Quantification of the ratio of cells in G1 phase to cells in S, G2 and M phases upon SMAD4 knockdown in 
M010817 and 501Mel cell lines.  
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Figure 2 Continues. Loss of Smad4 leads to decreased proliferation in established skin tumors. (H) 
Experimental strategy used to analyze effects on survival upon late deletion of Smad4 in Tyr::NrasQ61K Ink4-/- 
melanoma murine model. (I) Kaplan–Meier curves comparing melanoma-specific survival of control and Smad4 
cKO animals (n=11 (cKO), n=8 (control)). Data represented as the mean ± SEM. ns. non-significant, p< 0.01**, 
p< 0.001***. P values calculated with unpaired Student’s t-test (D-G) or with log-rank Mantel–Cox test (I). TM, 
tamoxifen. Scale Bars, 50μm. 
 
6.1.3 BMP7 signaling promotes melanoma cell growth 
 
Until now, members of the TGF-β superfamily have been associated with cytostatic and/or pro-invasive 
functions in melanoma cells (Siegel & Massagué 2003). However, our in vivo data indicate that one or 
more factors that signal through Smad4 must have the opposite effect, supporting tumor cell 
proliferation rather than cell cycle arrest. Most of the TGF-β family ligands known to elicit responses 
in human melanoma cells are expressed by the tumor cells themselves, where they induce their own 
expression through a positive amplification loop (Fimmel et al. 1999; Rothhammer et al. 2005; Stove 
et al. 2004; Topczewska et al. 2006). Likewise, several TGF-β superfamily factors, including notably 
TGF-β2 and BMP7, were concomitantly expressed by tumors derived from Tyr::NrasQ61K Ink4a−/− mice 
(Supplemental Figure 1A). Thus, we functionally investigated these factors in order to explore ligands 
potentially responsible for melanoma cell proliferation. Cell cycle analysis revealed that, among the 
factors analyzed, BMP7 could stimulate cell cycle progression in the two cell lines tested, with a 
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significant increase from 18 ± 1% and 18 ± 2% of cells in S phase in control cultures to 22 ± 3% and 
24 ± 3% after BMP7 treatment, respectively (Supplemental Figure 1, B and A). In contrast, the other 
TGF-β superfamily factors tested suppressed proliferation in human melanoma cells, as previously 
reported (Topczewska et al. 2006; Schlegel et al. 2009) (Supplemental Figure 1B and C). TGF-β2 and 
NODAL have been shown to induce invasiveness in melanoma cells (Topczewska et al. 2006; Schlegel 
et al. 2015). In agreement with these earlier reports, human melanoma cells exposed to TGF-β2 or 
NODAL, as much as BMP4, changed their morphology and exhibited a decreased cell-substrate 
adherence capacity (Supplemental Figure 1D). In contrast, BMP7 did not affect adhesiveness of human 
melanoma cells (Supplemental Figure 1D). 
 
To corroborate our data, we correlated expression levels of BMP7 and TGF-β2 with RNA-seq data 
obtained from various proliferative and invasive human melanoma cell lines in culture. Among others, 
TGF-β2 mRNA was robustly expressed in patient-derived cell cultures representing an invasive 
melanoma phenotype (WNT5Ahigh, SOX9high, ZEB1high, AXLhigh) (Supplementary Fig. S1e). In contrast, 
markers for proliferative melanoma cells (SOX10high, MITFhigh) correlated with BMP7 expression levels 
(Supplemental Figure 1E).  
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Supplementary Figure S1 BMP7 signaling promotes melanoma cell growth (a) log2 Fold change of ligand 
mRNAs in primary tumors derived from Tyr::NrasQ61K Ink4-/- murine melanoma model (n=7). qRT–PCR data 
represent the mean of transcript levels (Log2) in three biological samples for each condition. Boxplot whiskers 
indicate minimum and maximum expression. (b-c) M010817 and 501Mel cells were starved prior to 48 hours 
ligand treatment, using the ligand concentrations mentioned in Supplementary Table S7. Cells were stained with 
propidium iodide (PI) together with EdU and fluorescence intensity was measured by FACS analysis. Bars 
represent the percentage of cells distributed in S cell cycle phase. (d) Quantification of cell-substrate adherence 
capacity of melanoma cells. Cells in suspension that had detached upon ligand treatment were re-seeded on 
fibronectin-coated plates and adherent cell colonies were stained with crystal violet. The area covered by re-
attached cells was calculated by Cell Profiler. (e) Clustering of RNA-seq-based expression data revealing invasive 
and proliferative cell states in vitro. Samples in the invasive cluster have high expression of the following genes: 
WNT5A, AXL, ZEB1, SOX9, and TGF-β2. Genes with high expression in the proliferative sample cluster include 
BMP7 and known markers of the melanocyte lineage and melanoma, such as SOX10 and MITF. Correlations of 
RNA-seq expression data was as follows: BMP7 and MITF r= 0.43 ***p<0.001, BMP7 and SOX10 r=0.39 
***p<0.001, TGF-β2 and ZEB1 r=0.33 **p<0.01, TGF-β2 and AXL r=0.55 ***p<0.001, TGF-β2 and WNT5A 
r=0.63, TGF-β2 and SOX9 r=0.29, **p<0.01. 
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Supplementary Figure S1 Continues. BMP7 signaling promotes melanoma cell  growth pSMAD2/3 and 
pSMAD1/5/8 were detected in melanoma cells upon ligand treatment by using western blot analysis. (h) 
Quantification of western blot analysis, phosphorylation levels of SMAD2/3 and SMAD1/5/8 were determined 
by using phospho-SMAD specific antibodies and normalized to total SMAD2 and SMAD1/5 levels, respectively. 
Data are represented as a mean of three independent experiments ± SEM. P<0.05*, P<0.01**, P<0.001***. P 
values calculated with one-way ANOVA followed by comparisons to the control group with Bonferroni 
correction, adjusted α = 0.05/5 = 0.01, unpaired Student’s t-test (a-d) or Pearson correlation test (e). Data 
represented as a mean of three independent experiments ± SEM. P<0.001***. For (h), P values were calculated 
with unpaired Student’s t-test.  
 
Since activation of R-SMADs is required for canonical TGF-β signaling, we investigated whether 
proliferative vs. invasive ligands preferentially signal through specific SMADs. Western blot analysis 
for pSMAD1/5/8 and pSMAD2/3 (indicators of BMP and TGF-β signaling activity, respectively) 
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verified signaling specificity between different TGF-β superfamily members in human melanoma cells 
(Supplemental Figure. 1F, G and H). Remarkably, both BMP4 and BMP7 signaled through SMAD1/5/8 
phosphorylation, although BMP4 counteracted proliferation and induced an invasive program when 
added to melanoma cells, whereas BMP7 increased the percentage of cells in S phase (Supplemental 
Figure 1B and C). Thus, the distinct biological activities of TGF-β superfamily members cannot simply 
be explained by differential usage of the known canonical SMAD signaling pathway.  
 
6.1.4 Loss of SMAD7 is clinically relevant and associated with a MITFhigh/AXLhigh 
transcriptional state 
 
Our data show that certain TGF-β superfamily factors expressed in melanoma display opposite effects 
on cell growth and invasiveness. This suggests that growth and metastatic spread of melanoma are 
influenced through fine-tuning the activities of these factors. To identify modulators and effectors of 
TGF-β/SMAD signaling possibly relevant for melanoma progression, we first examined RNA 
sequencing (RNA-seq) and clinical data from The Cancer Genome Atlas (TCGA). Survival analysis of 
the TCGA melanoma dataset (TCGA-SKCM) showed that among 36 SMAD signaling components, 
the inhibitory SMAD protein SMAD7 stood out as the clinically most relevant factor (Figure 3A). In 
fact, patients with low SMAD7 transcript levels had significantly shorter overall survival as compared 
to those having high SMAD7 transcripts (p= 0.036) (Figure 3B). The SMAD7high and SMAD7low patient 
cohorts did not exhibit obvious differences with respect to clinically relevant BRAF and NRAS 
mutations (data not shown). The difference in survival was even more evident when comparing those 
SMAD7low and SMAD7high groups of patients that displayed advanced stage disease at the time of 
analysis (stage II – IV) (p= 0.0125) (Figure 3B). Finally, gene ontology (GO) analysis using differential 
gene signatures of SMAD7low and SMAD7high patients revealed that categories crucial for melanoma 
biology, such as regulation of EMT, cell adhesion and migration, cytoskeletal remodeling, as well as 
upregulation of MITF were significantly enriched (Figure 3C).  
 
 
 
63 
 
                      
                                     
                    
 
Figure 3. Low SMAD7 levels are associated with altered cell adhesion and cell cycle programs in human 
melanoma patients and patient-derived human melanoma cell lines. (A) P values are given for Kaplan Meier 
analysis comparing percent overall survival of melanoma patient cohorts based on TCGA data for 36 identified 
transcripts of TGF-β/BMP pathway components. For each gene, low/high expression levels of each gene were 
based on transcript levels found in bottom and top 50 patients, respectively. (B) Kaplan–Meier curves comparing 
overall percent survival with respect to SMAD7 transcript levels based on 350 patients. (C) Significantly changed 
top ten-ranking GeneGo process networks associated with low/high SMAD7 expression based on MetaCore 
Database. 
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Figure 3. Continues Low SMAD7 levels are associated with altered cell adhesion and cell cycle programs in 
human melanoma patients and patient-derived human melanoma cell lines. (D) Heat map showing genes 
differentially expressed in SMAD7 knockdown and control M010817 cells (3557 genes, row z-score from three 
replicate RNA sequencing experiments). The gene list was generated using a 1.5-fold-change cut-off, and p-value 
of 0.05. Of these, 1586 were up-regulated and 1971 commonly down-regulated. (E) Gene ontology analysis based 
on differentially regulated genes upon SMAD7 knockdown. Each individual node shows an enriched GO term p 
value < 0.05) (Corrected with Bonferroni step down procedure). BP, biological process; MF, molecular function; 
CC, cellular component. A fully labeled version is given in Supplementary Figure S3. (F)Heat map of 
differentially expressed EMT genes (n= 84/225). Red; increased, blue; decreased expression. Highlighted cells 
indicate invasive genes according to Verfaillie and colleagues. 39 (G, H) Venn diagram showing the overlap 
between MITFhigh and AXLhigh gene expression programs derived from patient melanoma samples obtained by 
single cell sequencing2 with genes changed between low/high expressing SMAD7 patients or upon siRNA-
mediated knock down of SMAD7 in M010817. Heat maps indicate differentially expressed MITF and AXL 
program genes, respectively.12 Gene list, see Supplemental Table S3 (H). 
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To address the physiological role of SMAD7 and its potential association with TGF-β signaling in 
melanoma cells, we first reduced SMAD7 levels by RNA interference-mediated silencing. This led to 
significant upregulation of both pSMAD2/3 and pSMAD1/5/8 expression, demonstrating the capacity 
of SMAD7 to inhibit canonical TGF-β signaling in melanoma cells (Supplemental Figure 2, A-F). To 
characterize the molecular pathways regulated by SMAD7-mediated signaling in melanoma, siSMAD7 
and siControl treated M010817 cells were subjected to RNA-seq. Similar to the TCGA patient analysis 
(Figure 3D), the GO analysis based on cytoscape demonstrated highly significant enrichment in 
pathways associated with cell cycle core components and cell-cell adhesion (Figure 3E, Supplementary 
Figure 2G and Supplemental Table 1). Specifically, a comprehensive EMT program, including cell-cell 
adhesion molecules and transcriptional regulators previously associated with an invasive gene signature 
in melanoma (Verfaillie et al. 2015), was upregulated upon knock down of SMAD7 (Figure 3F and 
Supplemental Table 2). Importantly, we also observed changes in a variety of crucial cell cycle 
regulators, such as cyclins, cyclin dependent kinases (CYCLINB1, CYCLINB2, CYCLIND1, 
CYCLIND2, CYCLINA, CYCLINE, CDK2, CDK4) and S phase genes (TOP2A, KI67) (Supplemental 
Figure 2G and Supplemental Table 1). 
 
6.1.5 Loss of SMAD7 boosts pro-invasive TGF-β/NODAL signaling in the presence of 
pro-proliferative BMP7 
 
According to our bioinformatics analysis, SMAD7 appears to be implicated in both cell cycle and cell 
adhesion/EMT control in melanoma. To functionally test this hypothesis, we performed SMAD7 loss-
of-function studies in the context of combinatorial TGF-β superfamily signaling. As expected, TGF-β2 
or NODAL treatment counteracted proliferation in human melanoma cells and reduced cell-substrate 
adhesiveness, which was accompanied by upregulation of an EMT gene expression signature 
characteristic for invasive melanoma (Figure 4, A and B; Supplementary Figure 3, A and B). 
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Supplementary Figure S2 Knock down of SMAD7 in human melanoma cell lines. (a-c) Western blot of 
M010817 whole cell extracts treated with SMAD7 siRNAs. (d-f), SMAD7 siRNA effects on phosphorylation of 
SMAD1/5/8 and SMAD2/3. Phosphorylation levels of SMAD2/3 and SMAD1/5/8 were determined by using 
phospho-SMAD specific antibodies and normalized to total SMAD2 and SMAD1/5 levels, respectively.  
An increase in the expression of EMT regulators has been reported before to anti-correlate with a 
MITFhigh gene expression program(Müller et al. 2014),(Richard et al. 2016). Moreover, the ratio of 
MITF/AXL expression has been used to define proliferative vs. invasive behaviors of melanoma 
cells(Cheli et al. 2011; Müller et al. 2014). Therefore, we next assessed which of the genes that 
constitute the published MITFhigh and AXLhigh programs(Tirosh et al. 2016) were differentially 
expressed in the TCGA-based SMAD7low patient group and in SMAD7-silenced human melanoma 
cells, respectively. Surprisingly, genes of both the MITF as well as the AXL program were mostly 
upregulated in SMAD7low patients or upon loss of SMAD7 (Figure 3, G and H; Supplemental Table 3) 
These data indicate that contrary to the reported MITFhigh/AXLlow and MITFlow/AXLhigh binary 
“phenotype switching” states, melanoma cells with decreased SMAD7 levels exhibit a 
MITFhigh/AXLhigh transcriptional state.  
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Silencing of SMAD7 reinforced these biological activities of TGF-β2/NODAL. Of note, BMP7 
stimulated proliferation of human melanoma cells even when added together with TGF-β2 and 
NODAL, respectively, at concentrations at which the latter factors alone decreased proliferation (Figure 
4, A and B; Supplemental Figure 3, A and B). Moreover, when melanoma cells were treated with TGF-
β2 or NODAL in combination with BMP7, the EMT signature of malignant melanoma was suppressed, 
and the cells failed to detach from the substrate (Figure 4, C-E; Supplemental Figure 3, C-E). Thus, in 
the presence of TGF-β2 or NODAL, pro-proliferative BMP7 is dominant and able to override the 
cytostatic, pro-invasive effects of TGF-β2/NODAL in human melanoma cells.  
 
 
 
Figure 4. Loss of Smad7 boosts pro-invasive TGF-β/NODAL signaling in the presence of pro-proliferative 
BMP7. A, B Quantification of cell cycle S phase measured 3 days post ligand treatment through PI and EdU 
staining. M010817 and 501Mel cells were treated either with TGF-β2 (10ng/μl), BMP7 (100ng/μl), or both, with 
or without siRNA-mediated SMAD7 knockdown. Treatment with BMP7 resulted in escape of cells from the TGF-
β2-mediated cell cycle arrest and increased proliferation. SMAD7 knock down of BMP7/TGF-β2-treated cells led 
to decreased numbers of cells in S cell cycle phase as compared to BMP7/TGF-β2-treated cells (n=3). 
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Figure 4. Continues Loss of Smad7 boosts pro-invasive TGF-β/NODAL signaling in the presence of pro-
proliferative BMP7. (c,d) Quantification of cell-substrate adherence capacity of M010817 and 501Mel cells upon 
treatment with TGF-β2, BMP7 (100ng/μl), or both, with or without siRNA-mediated SMAD7 knockdown. TGF-
β2-mediated cell detachment was suppressed by BMP7. The percentage of BMP7/TGF-β2/siSMAD7-treated cells 
in suspension increased as compared to BMP7/TGF-β2-treated cells (n=3).(e) Heat map shows qRT-PCR analysis 
for selected EMT genes under ligand treatments with two biological and three technical replicates. The expression 
levels of genes are presented using fold-change values transformed to Log2 format compared to control. Color 
represents expression after normalization to non-treated control cells. Data represented as a mean of three 
independent experiments ± SEM. P values calculated with one-way ANOVA followed by comparisons to the 
control group with Bonferroni correction (adjusted α = 0.05/5 = 0.01). P< 0.01**, P < 0.001*** (a-d).  
 
Surprisingly, however, downregulation of SMAD7 did not alter the cell cycle-promoting effect of 
BMP7 in human melanoma cells. Furthermore, addition of BMP7 reversed the cell cycle arrest observed 
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upon TGF-β2 plus siSMAD7 treatment, making co-treatment with TGF-β2/siSMAD7 compatible with 
proliferation (Figure 4, A and B). In contrast to the capacity of BMP7 to override the cytostatic effect 
of TGF-β2, BMP7 only partially counteracted the loss-of-adhesion phenotype mediated by TGF-
β2/siSMAD7. Although cell detachment in BMP7/TGF-β2/siSmad7-treated cells was not as prominent 
as in TGFβ-2/siSMAD7-treated cells, the number of cells in suspension was still significantly increased 
as compared to BMP7/TGFβ-2-treated cells, in which TGF-β2 signal activity had not been enhanced 
by siSMAD7 (Figure 4, C and D) 
 
Supplementary Figure S3 Cell cycle analysis upon combinatorial TGF-β superfamily factor treatment of 
human melanoma cell lines. (a,b) Quantification of cell cycle S phase was measured 3 days post treatment 
through PI and EdU staining. M010817 and 501Mel cells were treated with either TGF-β2 (10ng/μl), BMP7 
(100ng/μl) alone or both, together with siRNA mediated SMAD7 knockdown. Treatment with BMP7 resulted in 
escape of cells from the NODAL-mediated cell cycle arrest and increase in the proliferation rate. SMAD7 knock 
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down in BMP7/NODAL-treated cells results in decreased S cell cycle phase as compared to BMP7/NODAL-
treated cells. (c,d) Quantification of cell-substrate adherence capacity (see Supplementary Figure S1) of M010817 
and 501Mel cells treated with the indicated factor combinations. NODAL-mediated cell detachment was 
suppressed by BMP7. The percentage of BMP7/NODAL/siSmad7-treated cells in suspension increased as 
compared to BMP7/NODAL-treated cells (n=3).  
 
 
Supplementary Figure S3 Continues Cell cycle analysis upon combinatorial TGF-β superfamily factor 
treatment of human melanoma cell lines (e) Heat maps show the qRT-PCR analysis results of selected EMT 
genes under combinatorial ligand treatments. (a-e) Data represented as a mean of three independent experiments 
± SEM. P<0.05*, P<0.01**, P<0.001***. P values calculated with one-way ANOVA followed by comparisons 
to the control group with Bonferroni correction (adjusted α = 0.05/5 = 0.01). ***) 
 
Consistent with these observations, siSMAD7 treatment of cells concomitantly exposed to TGF-β2 and 
BMP7 restored an EMT gene expression signature characteristic for invasive melanoma cells (Figure 
4E). Similarly, the dominant anti-invasive activity of BMP7 over NODAL was reverted upon SMAD7 
knock down. While BMP7/NODAL-treated cells had a non-invasive phenotype, 
BMP7/NODAL/siSMAD7-treated cells displayed reduced cell adhesion and an EMT signature 
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reminiscent of invasive cells (Supplemental Figure 3, C-E). Nonetheless, BMP7/NODAL/siSMAD7-
treated cells exhibited a proliferative capacity comparable to that of control cells (Supplemental Figure 
3, A and B). Thus, reducing SMAD7 levels does not alter proliferation in vitro, but boosts the pro-
invasive activity of TGF-β2/NODAL even in the presence of BMP7. 
 
Contrary to the binary cell states proposed in the phenotype switching hypothesis, our finding suggests 
that reduced SMAD7 levels in the context of complex TGF-β superfamily signaling increases the 
invasive potential of melanoma cells while sustaining their proliferative capacity. To clarify whether 
these cells eventually retain cell proliferation and invasiveness, we pulsed human melanoma cells with 
the thymidine analogue EdU, which incorporates into replicating DNA during S phase, after 48 hours 
of silencing SMAD7 in the presence of pro-proliferative BMP7 and pro-invasive TGF-β2 (Figure 5A). 
Furthermore, we tested whether proliferative cells expressed the EMT-TF ZEB1, which is characteristic 
of invasive melanoma cells (Caramel et al. 2013). Strikingly, double staining revealed that cultures of 
BMP7/TGF-β2/siSMAD7-treated cells contained significantly higher numbers of EdU- and ZEB1-
double positive cells (23 ± 3%) in comparison to BMP7/TGF-β2 -treated (9 ± 2%) or untreated control 
cells (4 ± 1%) (Figure 5, B and C). 
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 Figure 5. Loss of SMAD7 promotes emergence of proliferative-invasive MITFhigh/AXLhigh melanoma 
cells in vitro (A) Experimental design used in this study. Proliferative M010807 cells were exposed to 
combinatorial ligand treatment over a 3-day period. Cells were pulsed with EdU, followed by flow cytometry. (B) 
Representative immunofluorescent images of ZEB1/EdU-double-positive cells (white arrowheads). Open 
arrowheads, EdU+/ZEB1- cells. (C) Quantification of single and double labeled cells for ZEB1 and EdU (n=3). 
 
De-regulated TGF-β/SMAD signaling can alter MITF expression depending on the melanoma cell line 
(Smith et al. 2013). Moreover, as mentioned before, the ratio of MITF/AXL expression has been used 
to distinguish proliferative and invasive melanoma cells (Cheli et al. 2011; Müller et al. 2014). 
Therefore, we also assessed the number of cells expressing high vs. low levels of MITF, together with 
AXL expression, upon combinatorial TGF-β superfamily treatment. Importantly, in untreated cultures, 
in cultures exposed to various combinations of TGF-β superfamily factors, and in siSMAD7-treated 
cultures in the absence of exogenous TGF-β factors, AXL-positive cells were MITFlow, and only a minor 
fraction of cells expressed both AXL and high levels of MITF. In contrast, the number of cells that were 
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double positive for AXL and high MITF was significantly increased to 18 ± 3% of all cells upon 
concomitant BMP7/TGF-β2/siSMAD7 treatment (Figure 5, D and E). Together, these data indicate that 
reducing SMAD7 levels endows proliferative melanoma cells with invasive capacity, which possibly 
contributes to melanoma cell aggressiveness.  
 
 
Figure 5. Continues. Loss of SMAD7 promotes emergence of proliferative-invasive MITFhigh/AXLhigh 
melanoma cells in vitro  (D) Representative immunofluorescent images of MITFhigh/AXLhigh-double-positive 
cells. (E) Quantification of cells expressing AXL, MITFhigh, or both (n=3). Data represented as a mean of three 
independent experiments ± SEM. p < 0.001***. P values calculated with unpaired Student’s t-test (C,E). Scale 
Bars, 50μm. 
 
6.1.6 Loss of Smad7 in vivo increases the number of cells with both invasive and 
proliferative features 
 
Our cell culture data revealed the presence of cells that acquired both invasive and proliferative features 
upon SMAD7 inactivation. To corroborate these in vitro findings in a physiologically more relevant 
setting, we assessed whether Smad7 might also modulate the output of integrated TGF-β/SMAD 
signaling in vivo. As shown above, TGF-β superfamily factors, including TGF-β, NODAL, as well as 
BMP7 were expressed in melanoma cells derived from Tyr::NrasQ61K Ink4a-/- Tyr::CreERT2 R26R::LacZ 
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mice (Supplemental Figure 1A). To functionally study the role of Smad7 in melanoma progression, we 
mated mice carrying a floxed allele of Smad7(Kleiter et al. 2010) with the Tyr::NrasQ61KInk4-/- 
melanoma mouse model to obtain Tyr::NrasQ61K Ink4a-/- Tyr::CreERT2 Smad7lox/lox R26R::LacZ mice 
(Figure 6, A and B). TM-mediated Tyr::CreERT2 activation in these mice at 1 month of age resulted in 
efficient recombination and depletion of Smad7 protein in Dct-expressing melanoma cells 
(Supplemental Figure 4, A and B). Importantly, loss of Smad7 led to a substantial increase in the 
percentage of Dct-positive melanocytic cells co-expressing nuclear pSmad2/3 and pSmad1/5/8, 
demonstrating activation of both canonical SMAD signaling pathways (Supplemental Figure 4, D and 
E). Despite signal activation, however, conditional depletion of Smad7 neither had an overt effect on 
hyperplastic dermal lesions (data not shown) nor on the number of skin melanomas emerging during 
disease progression (Figure 6C). Consistent with this, EdU incorporation into primary tumors was not 
significantly altered in Smad7 cKO as compared to control mice (34 ± 1% vs. 37 ±3%) (Figure 6D). 
Next, we assessed Zeb1 expression in primary tumors of Tyr::NrasQ61K Ink4a-/- Tyr::CreERT2 Smad7lox/lox 
R26R::LacZ mice after EdU application. Intriguingly, the number of Zeb1/EdU double-positive cells 
was significantly higher (16 ± 4%) in primary tumors of Smad7 cKO mice when compared to control 
primary tumors (4 ± 2%) (Figure 6, D and E). To verify that the induction of Zeb1 expression in 
proliferative cells represented a malignant cell phenotype, we additionally quantified the number of 
Mitfhigh/Axl-double-positive cells in skin sections of Smad7 cKO mice. Notably, hyperplastic lesions 
displayed significantly higher numbers of double-positive cells (10 ± 2%) compared to control skin 
sections (2 ± 1%). Similarly, the number of Mitfhigh/Axl-double-positive cells was dramatically 
increased in primary tumors of Smad7 cKO mice (27 ± 3%) when compared to control tumors (6 ± 1%) 
(Figure 6, F-H). 
 
Together, our findings suggest that inactivation of Smad7 and a concomitant increase in pSmad2/3 and 
pSmad1/5/8 does not interfere with tumor growth in vivo, despite increased expression of the invasive 
marker Zeb1 in EdU-positive proliferating cells. Importantly, we also observed an increase in Axl 
expression in Mitfhigh proliferative cells upon Smad7 deletion in primary tumors indicating that 
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augmented SMAD signaling increases the number of cells associated with both high proliferation and 
invasion properties. 
 
 
 
Figure 6. Loss of Smad7 promotes emergence of proliferative-invasive MITFhigh/AXLhigh melanoma cells 
in vivo (A) The melanoma mouse model used to analyze the effect of Smad7 conditional deletion in Tyr::CreERT2 
Tyr::NrasQ61K INK4a−/− mice. (B) Experimental strategy used to analyze the proliferation rate by EdU injection 
upon Smad7 loss. (C) Quantification of the number of skin melanomas of control and Smad7 cKO mice (n=12). 
(D,E) Immunostaining and quantification of EdU/Zeb1-double positive cells in Smad7 cKO and control primary 
tumors. Grey and white bars indicate single Zeb1+ and EdU+ cells, respectively. Yellow bar represents percentage 
of EdU+ cells that are Zeb1+. White arrowheads in the images indicate double-positive cells, open arrowheads 
EdU+/Zeb1- cells 
 
To verify that the induction of Zeb1 expression in proliferative cells represented a malignant cell 
phenotype, we additionally quantified the number of Mitfhigh/Axl-double-positive cells in skin sections 
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of Smad7 cKO mice. Notably, hyperplastic lesions displayed significantly higher numbers of double-
positive cells (10 ± 2%) compared to control skin sections (2 ± 1%). Similarly, the number of 
Mitfhigh/Axl-double-positive cells was dramatically increased in primary tumors of Smad7 cKO mice 
(27 ± 3%) when compared to control tumors (6 ± 1%) (Figure 6, F-H). 
 
Together, our findings suggest that inactivation of Smad7 and a concomitant increase in pSmad2/3 and 
pSmad1/5/8 does not interfere with tumor growth in vivo, despite increased expression of the invasive 
marker Zeb1 in EdU-positive proliferating cells. Importantly, we also observed an increase in Axl 
expression in Mitfhigh proliferative cells upon Smad7 deletion in primary tumors indicating that 
augmented SMAD signaling increases the number of cells associated with both high proliferation and 
invasion properties. 
 
 
Figure 6. Loss of Smad7 promotes emergence of proliferative-invasive MITFhigh/AXLhigh melanoma cells 
in vivo.  (F-H) Quantification and immunostaining of Mitfhigh/Axl-double positive cells in cKO and control 
primary tumors. Percentage of Mitfhigh/Axl-double positive cells calculated over overall number of Mitfhigh and 
Mitflow cells. Yellow bar represents percentage of Mitfhigh cells that are Axl+. Arrowheads in the images indicate 
the double-positive cells, open arrowheads Mitf+/Axl- cells. Data represented as the mean ± SEM. p < 0.001***. 
P values calculated with unpaired Student’s t-test (C-F). Epi, Epidermis; TM, tamoxifen. Scale Bars, 50μm. 
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6.1.7 Reduced Smad7 expression promotes massive metastatic spread of melanoma in 
vivo 
Despite apparently unaltered tumor initiation and primary tumor growth, Smad7 cKO mice displayed 
significantly reduced melanoma free survival (Figure 7A). When analyzing these mice, we observed a 
massive metastatic spread to organs such as the lung, spleen and the liver, which were normally devoid 
of metastases in control mice (Figure 7B). Pigment-associated Dct-positive cells in these distant 
metastases did not express Smad7, demonstrating their origin from Smad7-depleted recombined 
melanoma cells (Figure 7C). Quantification of the metastatic burden in lung, spleen, and liver confirmed 
the high aggressiveness of melanoma caused by Smad7 inactivation (Figure 7, D-F).  
 
In the above experiment, Smad7 inactivation was broadly induced in melanocytic cells by systemic TM 
treatment. To assess whether restricted depletion of Smad7 is sufficient to promote melanoma 
metastasis formation, we locally applied 4-OH-TM to the back skin of Tyr::NrasQ61K Ink4a-/- 
Tyr::CreERT2 Smad7lox/lox R26R::LacZ mice (Figure 7G). Although recombination efficiency in the 
treated areas was lower than in melanocytic skin cells after systemic TM treatment (Supplemental 
Figure 4B), a reduction in overall survival of mice was observed (Supplemental Figure 4F). Importantly, 
at the day of sacrifice, the number of lung macro metastases was highly increased upon local Smad7 
depletion, demonstrating the striking metastatic potential of Smad7 cKO skin melanoma cells (Figure 
7H). Thus, loss of Smad7 significantly increases the aggressiveness of melanoma in the context of 
enhanced pSmad2/3 and pSmad1/5/8 signal activation. 
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Supplementary Figure S4 Reduced Smad7 expression promotes massive metastatic spread of melanoma in 
vivo. (a) Immunofluorescent staining for Smad7 and Dct on back skin sections at 6 months of age. Melanocytic 
cells are recombined and show decreased levels of Smad7 (n=6). (b) Quantification of the recombination 
efficiency by analyzing the percentage of Dct/β-Gal+ double-positive cells upon intraperitoneal injection and upon 
local application of 4-hyroxytamoxifen (4-HT) to the back skin of 3 week old mice (n=6). (c) Representative 
hematoxylin and eosin staining of lung and spleen sections of control and cKO mice at the day of sacrifice. X-Gal 
staining (blue) illustrates presence of recombined metastatic cells in distant organs. 
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Figure 7. Reduced Smad7 expression promotes metastatic spread of melanoma in vivo (A) Kaplan–Meier 
curves comparing melanoma-specific survival of control and Smad7 cKO animals (n=35 (cKO), n=30 (control)). 
(B) Representative pictures of indicated organ from Smad7 cKO and control animals. (C) Immunofluorescent 
staining for Smad7 and Dct at the site of distant metastasis in Smad7 cKO and control animals. Note absence of 
Smad7 expression in pigmented Dct+ areas. (D-F) Quantification of macro-metastasis numbers in lung, spleen 
and liver in Smad7 cKO and control littermates 
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In the above experiment, Smad7 inactivation was broadly induced in melanocytic cells by systemic TM 
treatment. To assess whether restricted depletion of Smad7 is sufficient to promote melanoma 
metastasis formation, we locally applied 4-OH-TM to the back skin of Tyr::NrasQ61K Ink4a-/- 
Tyr::CreERT2 Smad7lox/lox R26R::LacZ mice (Figure 7G). Although recombination efficiency in the 
treated areas was lower than in melanocytic skin cells after systemic TM treatment (Supplemental 
Figure 4B), a reduction in overall survival of mice was observed (Supplemental Figure 4F). Importantly, 
at the day of sacrifice, the number of lung macro metastases was highly increased upon local Smad7 
depletion, demonstrating the striking metastatic potential of Smad7 cKO skin melanoma cells (Figure 
7H). Thus, loss of Smad7 significantly increases the aggressiveness of melanoma in the context of 
enhanced pSmad2/3 and pSmad1/5/8 signal activation. 
 
 
 
Figure 7. Continues. Reduced Smad7 expression promotes metastatic spread of melanoma in vivo (G) 
Experimental strategy used to analyze the effect of local Smad7 loss in Tyr::N-RasQ61K Ink4a−/− Tyr::CreERT2 
R26R::LacZ mice by 4-HT administration to the skin. (H) Kaplan–Meier curves comparing melanoma-specific 
survival of control mice and animals, in which Smad7 has been locally deleted in the skin of 3 week old mice (n= 
12 (cKO), n=12 (control)). Data represented as a mean of three independent experiments ± SEM. p<0.01**, 
p<0.001***. P values calculated with unpaired Student’s t-test (D-F), or log-rank Mantel–Cox test (A), (H). TM, 
tamoxifen, 4-HT, 4-hydoxytamoxifen. Scale Bar, 50μm. 
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Supplementary Figure S4. Continues Reduced Smad7 expression promotes massive metastatic spread of 
melanoma in vivo. (d) Immunofluorescent staining for pSmad2/3, pSmad1/5/8 and Dct of primary tumors at 6 
months (n=6). Control and cKO primary tumors were quantified for active TGF-β signaling by detecting the 
nuclear localization of pSmad2/3 or pSmad1/5/8 (n=6). (e) Quantification of active TGFβ signaling by quantifying 
number of melanocytic Dct+ cells displaying nuclear localization of pSmad2/3 and pSmad1/5/8, respectively, in 
primary tumors at 6 months (n=6). (f) Kaplan–Meier curves comparing overall survival between 4-HT treated 
animals and control animals (n=8). Data represented as a mean of three independent experiments ± SEM. P values 
calculated with unpaired Student’s t-test (b), Tukey’s post-test following one-way ANOVA (d), or log-rank 
(Mantel–Cox) test (f). P< 0.05*, P< 0.01**, P< 0.001***. Scale Bars: 50μm (a,d) 
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7. Methods 
All detailed information on experimental procedures and reagents is provided in the Supplementary 
Tables and Supplemental Experimental Procedures. 
7.1 Mice 
 
Animal experiments were done in accordance with a protocol approved by the veterinary authorities of 
the Canton of Zurich, Switzerland, and were performed in accordance with Swiss law, Welfare, and 
Treatment of Animals. All implementations were carried out in Tyr::NrasQ61K Ink4a-/- Tyr::CreERT2 
R26R::LacZ animals that were having a mixed genetic background. Animals homozygous for the floxed 
Smad7 (B6.Cg-Smad7tm1.1Ink/J) (Kleiter et al. 2010) allele or the floxed Smad4 allele (Smad4tm2.1Cxd/J) 
(Yang et al. 2002) were mated with mice heterozygous for the respective floxed allele(s) and carrying 
the Cre-recombinase. To conditionally delete genes of interests in the melanocytic linage, Tyr::CreERT2 
line was used (provided by L. Chin, The University of Texas MD Anderson Cancer Center, Houston, 
Texas, USA). Genotyping was done by PCR on genomic DNA (Qiagen Taq PCR Core Kit 201225), 
using the primer pairs indicated in (Supplemental Table 4). DNA was prepared and the reactions were 
carried out as described (Yang et al. 2002; Kleiter et al. 2010) No change in the expected gender and 
Mendelian inheritance ratio was found. Mice were often examined and sacrificed at an endpoint defined 
by adverse clinical symptoms, such as multiple skin tumours (Ø > 5mm), weight loss (> 15%), or 
hunched back. 
 
7.2 Immunofluorescent on cells 
 
Cells were grown on cover slips, ethanol-fixed, and subjected to immunofluorescent labelling using 
primary antibodies (Supplemental Table 5) in blocking buffer (1% BSA in PBS and 0.05% Tween) 
overnight at 4°C and secondary antibodies (Supplemental Table 5) for 1h at room temperature. Nuclei 
were stained with Hoechst 33342 (14533, Sigma-Aldrich), and cells were recorded with a DMI 6000B 
microscope (Leica). 
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7.3 Administration of tamoxifen and analysis of mice 
 
Transgenic lines were crossed to the Rosa26 Cre reporter strain (R26R), which has an ubiquitously 
expressed transgene containing a STOP cassette flanked by loxP sites followed by the LacZ gene. The 
resulting mice Tyr::NrasQ61K Ink4a-/- Smad4lox/lox R26R::LacZ  mice,  Tyr::NrasQ61K Ink4a-/- Smad4lox/wt 
Tyr::CreERT2 R26R::LacZ mice (control groups) and Tyr::NrasQ61K Ink4a-/- Smad4lox/lox Tyr::CreERT2 
R26R::LacZ mice (experimental group) were subjected to treatment with tamoxifen (T5648, Sigma 
Aldrich), which was diluted in ethanol and sunflower oil (1:9 ratio). Conditional ablation of Smad4 as 
well as Smad7 was achieved by intraperitoneal injections of tamoxifen (100 μl, 1 mg d−1 for 5 days) into 
4-week-old mice and 4-months-old mice. Topical administration of 4- hydroxytamoxifen (4-HT) was 
performed by preparing a 50mg/ml (130mM) solution of 4-HT (70% Z-isomer, Sigma) in dimethyl 
sulfoxide; DMSO. 4-week-old mice were treated with Veet cream to remove hair from 2 x 2 cm patch 
of skin on the dorsal flank. After the area was dried and topical administration of 50mg/ml stock solution 
in DMSO was diluted into 100% ethanol and freshly applied (1ml, for 3 days). Upon intraperitoneal 
(IP) Tamoxifen injections or topical 4-HT administration, mice were monitored for tumor numbers and 
development. In combination with staining for the R26R::LacZ Cre-reporter allele, the macroscopic 
skin phenotype was analysed histologically. Mice were examined regularly and sacrificed at an endpoint 
defined by adverse clinical symptoms including skin tumor size (Ø > 2mm), weight loss, or hunched 
back.  
 
7.4 Quantification of skin melanomas and metastases  
 
At day of sacrifice, skin melanoma numbers were counted. Non-recombined tumors were excluded for 
statistical analysis. Both in conditional Smad4 and Smad7 knockout mice (cKO), whole mount X-Gal 
staining was used to assess the recombined tumors. Quantification of the percentage of mice bearing 
macro-metastases in each organ including lung, liver and spleen were visually examined under the 
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binocular at necropsy and calculated by counting pigmented lesions at the organ surface. Affected 
lymph nodes (accessory axillary, proper axillary, sciatic and subiliac lymph nodes) were further 
assessed by immunohistostaining. PAX3, DCT and HMB-45 positivity was used to detect melanoma 
cells on lung, liver, and spleen on histological sections.   
 
7.5 Histologic analysis and immunohistochemistry  
 
Mice were sacrificed by CO2 inhalation. Samples were fixed in 4% (w/v) paraformaldehyde overnight. 
To achieve whole mount X-Gal staining, samples were fixed in 4% paraformaldehyde for only 20min 
and subjected to X-Gal staining. Sections (5μm) were stained with H&E, and serial sections were used 
for immunohistochemical analysis. Sections were deparaffinized and subjected to an antigen retrieval 
step using citrate buffer (S2369, Dako) (Rapid Microwave Histoprocessor, Milestone). Primary 
antibodies (Supplementary Table S5) were applied in blocking buffer (1% BSA in PBS and 0.05% 
Triton X-100) overnight at 4ºC and visualized using secondary antibodies (Supplementary Table S5) in 
blocking buffer for 1h at room temperature.  Antigen retrieval with heating in citric acid (pH 6.0) was 
done. Heavily pigmented skin slides were pre-treated with 0.1% KMnO4 for 20 minutes followed by 
0.5% oxalic acid for 12 minutes to increase the solution permeabilization. For visualization of β-
Galactosidase and phospho-SMADs, biotin anti-chicken and biotin anti-rabbit secondary antibodies 
was combined with further signal amplification using horse radish peroxidase–streptavidin and the TSA 
Plus Cy3 Kit (1:50, NEL744001KT, PerkinElmer) according to manufacturers’ protocol. Subsequently, 
nuclei were stained with Hoechst 33342 (14533, Sigma-Aldrich) slides were mounted with Fluorescent 
Mounting Medium (S3023, Dako). Immunohistochemical / fluorescent sections were analysed using 
either a Mirax Midi Slide Scanner (Zeiss) or a DMI 6000B microscope. Recombination efficiency of 
the Rosa26 allele was examined in mice by counting the β-Gal fluorescent cells of each tumor and 
dividing by the total number of DAPI-positive cells. Analysis of metastases was performed by counting 
distinct melanoma markers in each lesion (in sections from each level throughout the organ). Lung, 
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spleen and liver metastases were analysed based on the number of Pax3, Dct fluorescent cells. 
Groupings included single (1 cell), micro (11–100 cells), and macro (>100 cells). 
 
7.6 Analysis of proliferation and apoptosis 
 
To study tumor proliferation index, we investigated the incorporation of the thymidine analog 5-
ethynyl-2’-deoxyuridine (EdU). Prior to sacrifice under isoflurane anaesthesia, mice were injected IP 
with 50mg EdU / kg body weight. EdU was immunohistochemically detected on formalin-fixed and 
paraffin-embedded sections according to the manufacturer’s guidelines. (Click-iT® EdU Alexa Fluor® 
488 Imaging Kit, C310337, Invitrogen). Cell proliferation was also assessed by Ki67 immunostaining. 
To quantify cells undergoing apoptosis, cleaved caspase-3 staining was used (see Histologic Analysis). 
Ten high-power fields (40 magnification) from at least 3 independent mice were counted for positive 
staining. Quantitative analysis was performed by counting cells in 10 independent high-power fields 
(40×) per age-matched tissue section from six mice per group. 
 
7.7 Correlation Analysis 
 
Melanoma cell cultures were established from surplus material from primary cutaneous melanoma and 
melanoma metastases removed by surgery as previously described.(Raaijmakers et al. 2015) This was 
performed at Dermatology Department of University of Zurich. Cell lines were correlated to their high 
SOX10 and high MITF expression as proliferative and high WNT5A high ZEB1 and SOX9 expression 
as invasive. Pearson’s product moment correlation (r) was calculated for each gene expression values 
across all patient derived human melanoma cell lines. P-value was determined from the t statistic 
calculated from R value. 
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7.8 Cell culture, Cell Cycle Analysis and Ligand Treatments 
 
The 501Mel cell line was obtained from the ATCC collection. The 501Mel cell line carries 
BRAFV600Emutation. M010817 cell line were described previously (Hoek et al. 2006). The M010817 
cell line has NRASQ61R mutation (BRAF not mutated). Primary cells derived from Tyr::NrasQ61K Ink4a-/ 
-induced tumours were cultured as previously specified (Zingg et al. 2015). Cells were grown in RPMI-
1640 medium supplemented with 10% FCS and 4 mM L-glutamine. Ligand treatment experiments 
were studied in serum-starved medium (0.5% FCS) (24 hours starved before ligand treatment). The 
effect of ligands on cell phenotype was determined by continuously adding human recombinant ligands 
that are indicated Supplementary Table S5 for 72 hours to cell monolayers at 70% confluency. For cell 
cycle analysis, the Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Invitrogen) was used. 
Cells were labelled with PI according to the manufacturer’s protocol and the DNA content was 
measured using a BD FACS Canto II flow cytometer (BD Biosciences) and BD FACS Diva software 
(BD Biosciences).  
 
7.8 RNA Interference 
 
Silencing RNA (siRNA) transfection of human melanoma cells was carried out using jet PRIME siRNA 
Transfection Reagent (114-07, Polypus Transfection) solution according to the manufacturer’s 
protocol. To achieve gene specific knockdown of SMAD4 and SMAD7, human melanoma cells were 
transfected with siRNA (25nM) (Invitrogen) 72 hours before RNA and protein isolation 
(Supplementary Table S6). As control, scrambled siRNAs with similar guanine cytosine (GC) content 
were also purchased from Invitrogen and used as negative controls. We confirmed the specificity of 
these sequences in BLAST. Growth medium was exchanged after 24h and cells were subjected to 
further assays.  
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7.9 Quantitative RT-PCR and RNA Sequencing 
 
Total RNA was prepared using RNeasy Mini Kit (74104, Qiagen) and the RNase-Free DNase Set 
(79254, Qiagen) according to manufacturer’s guidelines, reverse transcribed with Maxima First Strand 
cDNA Synthesis Kit (K1641, Thermo Scientific) followed by an RNase H (EN0202, Thermo Scientific) 
digestion step. Real-time quantitative PCR (qPCR) was performed on a LightCycler 480 System 
(Roche) using LightCycler 480 SYBR Green I Master (4707516001, Roche). Control of genomic 
contamination was measured for each sample by performing the same procedure with or without reverse 
transcriptase. Primers used mentioned in (Supplementary Table S4). Relative quantitative RNA was 
normalized using the housekeeping genes β-actin and Gapdh. The entire procedure was repeated in 
three biologically independent samples. Results were presented as the fold change over controls isolated 
from the same experiments. Fold induction was calculated using the comparative Ct method (DDCt). 
Total RNA obtained from 3 control and 3 siRNA mediated knockdown samples. samples Quality 
checked were done by using Bio-Analyzer and samples were subjected to sequencing on Illumina Hiseq 
platform at the Functional Genomics Center Zurich (http://www.fgcz.ch/). Differential gene expression 
analysis was performed using a minimum fold change of 1.5 and a False Discovery Rate inferior to 
0.05. Gene ontology network analysis was performed with ClueGO (Version 2.3.2) and Cytoscape 
(Version 3.4.0). Clusters with less than 10 nodes were omitted. 
 
7.9 Protein Isolation and Western Blotting 
 
Cells were lysed in RIPA buffer (89900, Thermo Scientific) including Halt Phosphatase and Protease 
Inhibitor Cocktail (78420, 87786, Thermo Scientific. SDS–PAGE was carried out with 20 μg of whole-
cell protein lysate using 4–20% Mini-PROTEAN TGX Gels (456–1094, Bio Rad). The gels were 
blotted onto nitrocellulose membrane and blocked for 1h in Odyssey blocking buffer (927-40000, LI-
COR Biosciences). Primary antibodies (Supplementary Table S5) were applied in blocking buffer 
overnight at 4ºC and visualized using secondary antibodies (Supplementary Table S5) for 45 min at 
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room temperature. Blots were scanned and quantified with an Odyssey imaging system (LI-COR 
Biosciences). Quantified band intensities were normalized using either β-Actin or α-Tubulin as 
housekeeping protein. 
 
7.10 TCGA Analysis  
 
The RNAseq and clinical data sets for skin cutaneous melanoma were downloaded on April 2016 from 
TCGA (http://cancergenome.nih.gov/). Normalized reads from the level 3 RNA-seq data were used for 
analysis. Specimens with top and bottom transcript levels for a gene of interest were used for analysis. 
Patient numbers were gradually increased from a minimum of top and bottom 11% (50 out of 470) to a 
maximum of top and bottom 11 % (50 out of 470) to optimize potential segregation of Kaplan–Meier 
curves.  
 
7.11 Attachment Assay Using Fibronectin-Coated Plates 
Six well plates were coated with 1.25 Ag/mL of fibronectin (F1141-5MG, Sigma) in PBS overnight at 
4C. Wells coated with bovine serum albumin served as negative controls. .10 X104 cells were seeded 
in each well at 37ºC. After ligand treatment, suspension cells were collected and were seeded in each 
fibronectin-coated well at 37ºC. Unattached cells were discarded and the attached cells were gently 
washed with PBS. Cells were fixed with 1% formaldehyde for 10 min and stained with 0.5% crystal 
violet for 30 min and solubilized with methanol. The area was calculated using Cell Profiler Program. 
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7.12 Supplementary Tables 
7.12.1 Supplementary Table 1. GO Process 
NODE GOID GOTerm P-Value 
% Associated 
Genes 
Nr. 
Genes 
1 GO:0092561 DNA-dependent DNA replication 130.0E-6 19.11 30.00 
2 GO:0092562 DNA replication 13.0E-9 17.27 57.00 
3 GO:0006259 DNA metabolic process 1.3E-3 10.37 107.00 
4 GO:0044774 DNA replication initiation 550.0E-6 32.56 14.00 
5 GO:0044765 Regulation of transcription involved in G1/S  1.2E-3 39.29 11.00 
6 GO:0044774 G1/S transition of mitotic cell cycle 19.0E-6 16.80 42.00 
7 GO:0044773 cell cycle G1/S phase transition 25.0E-6 16.41 43.00 
8 GO:0098778 cell cycle phase transition 1.1E-3 11.99 68.00 
9 GO:9087689 mitotic cell cycle phase transition 890.0E-6 12.24 66.00 
10 GO:8976810 mitotic cell cycle process 4.1E-12 13.40 126.00 
11 GO:0000278 mitotic cell cycle 2.0E-12 13.06 135.00 
12 GO:0051726 regulation of cell cycle 11.0E-12 12.80 135.00 
13 GO:0007346 regulation of mitotic cell cycle 32.0E-3 11.43 59.00 
15 GO:0045786 negative regulation of cell cycle 14.0E-9 14.44 80.00 
16 GO:0000075 cell cycle checkpoint 430.0E-9 18.15 45.00 
17 GO:0031570 DNA integrity checkpoint 7.7E-3 16.20 29.00 
18 GO:0007049 cell cycle 1.9E-15 11.72 211.00 
19 GO:0007067 mitotic nuclear division 60.0E-9 15.07 69.00 
20 GO:0022402 cell cycle process 100.0E-12 11.69 160.00 
21 GO:0000280 nuclear division 450.0E-9 13.41 81.00 
22 GO:0007088 regulation of mitotic nuclear division 290.0E-6 19.31 28.00 
23 GO:0051301 cell division 41.0E-6 12.63 75.00 
25 GO:0051276 chromosome organization 340.0E-6 11.84 78.00 
26 GO:0071103 DNA conformation change 14.0E-3 13.78 39.00 
27 GO:0000070 mitotic sister chromatid segregation 27.0E-3 16.78 24.00 
28 GO:0007059 chromosome segregation 49.0E-6 14.78 51.00 
29 GO:0044427 chromosomal part 15.0E-3 10.40 88.00 
30 GO:0051783 regulation of nuclear division 36.0E-6 18.97 33.00 
31 GO:0005694 chromosome 4.2E-3 10.33 99.00 
32 GO:0051304 chromosome separation 44.0E-3 21.05 16.00 
33 GO:0098609 cell-cell adhesion 14.0E-3 9.65 117.00 
34 GO:0030155 regulation of cell adhesion 49.0E-3 10.60 73.00 
35 GO:0050865 regulation of cell activation 6.3E-3 11.76 64.00 
36 GO:0001775 cell activation 6.4E-6 11.42 110.00 
37 GO:0045321 leukocyte activation 1.7E-3 11.01 87.00 
38 GO:0098602 single organism cell adhesion 18.0E-3 10.40 86.00 
39 GO:0016337 single organismal cell-cell adhesion 24.0E-3 10.53 81.00 
40 GO:0002682 regulation of immune system process 12.0E-3 9.37 136.00 
41 GO:0051240 positive regulation of multicellular process 5.8E-6 10.28 155.00 
42 GO:0051094 positive regulation of developmental process 40.0E-6 10.49 129.00 
43 GO:0045597 positive regulation of cell differentiation 9.1E-3 10.41 92.00 
45 GO:0051241 process 43.0E-3 9.71 104.00 
46 GO:0051239 regulation of multicellular organismal process 180.0E-9 9.35 258.00 
47 GO:0022008 neurogenesis 40.0E-3 9.12 138.00 
48 GO:0032101 regulation of response to external stimulus 5.2E-3 10.88 83.00 
49 GO:0050793 regulation of developmental process 3.5E-6 9.41 222.00 
50 GO:0030154 cell differentiation 10.0E-9 8.98 339.00 
51 GO:0048731 system development 2.3E-12 9.08 405.00 
52 GO:0048869 cellular developmental process 780.0E-12 9.03 358.00 
53 GO:0048468 cell development 6.8E-3 8.94 177.00 
54 GO:0051128 regulation of cellular component organization 17.0E-3 8.57 206.00 
55 GO:0050793 regulation of developmental process 3.5E-6 9.41 222.00 
57 GO:0051240 positive regulation of multicellular organismal process 5.8E-6 10.28 155.00 
57 GO:0048513 animal organ development 43.0E-6 8.68 284.00 
58 GO:0009888 tissue development 5.0E-6 9.85 182.00 
59 GO:0009653 anatomical structure morphogenesis 100.0E-9 9.57 241.00 
59 GO:0007399 nervous system development 700.0E-6 8.98 205.00 
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NODE GOID GOTerm P-Value 
% Associated 
Genes 
Nr. 
Genes 
60 GO:0009790 embryo development 26.0E-3 9.89 100.00 
61 GO:0072359 circulatory system development 29.0E-6 11.07 111.00 
62 GO:0048646 morphogenesis 500.0E-9 11.55 119.00 
63 GO:0072358 cardiovascular system development 320.0E-6 11.89 78.00 
64 GO:0048514 blood vessel morphogenesis 13.0E-3 11.55 62.00 
65 GO:0001944 vasculature development 160.0E-6 12.06 78.00 
66 GO:0001568 blood vessel development 250.0E-6 12.04 75.00 
67 GO:0043542 endothelial cell migration 9.1E-3 16.37 28.00 
68 GO:0010631 epithelial cell migration 980.0E-6 15.51 38.00 
69 GO:0001667 ameboidal-type cell migration 3.4E-3 13.35 47.00 
70 GO:0090132 epithelium migration 1.2E-3 15.32 38.00 
71 GO:0090130 tissue migration 830.0E-6 15.35 39.00 
72 GO:0040017 positive regulation of locomotion 2.5E-3 12.45 58.00 
73 GO:0030335 positive regulation of cell migration 1.0E-3 13.10 55.00 
74 GO:2000147 positive regulation of cell motility 2.8E-3 12.67 55.00 
75 GO:0016477 cell migration 4.5E-12 12.17 157.00 
76 GO:0048870 cell motility 280.0E-12 11.49 163.00 
77 GO:0040012 regulation of locomotion 1.7E-3 10.83 91.00 
78 GO:2000145 regulation of cell motility 1.3E-3 11.11 86.00 
79 GO:0051272 positive regulation of cellular component movement 1.3E-3 12.81 57.00 
80 GO:0051270 regulation of cellular component movement 270.0E-6 11.14 94.00 
81 GO:0030334 regulation of cell migration 220.0E-6 11.63 84.00 
82 GO:0006928 movement of cell or subcellular component 96.0E-12 10.79 203.00 
83 GO:0050900 leukocyte migration 820.0E-6 13.38 53.00 
84 GO:0032879 regulation of localization 52.0E-6 9.02 233.00 
85 GO:0006935 chemotaxis 1.2E-3 11.86 70.00 
86 GO:0042330 taxis 740.0E-6 12.01 71.00 
87 GO:0071621 granulocyte chemotaxis 16.0E-3 18.75 21.00 
88 GO:0097530 granulocyte migration 25.0E-3 17.74 22.00 
89 GO:0097529 myeloid leukocyte migration 6.1E-3 16.38 29.00 
90 GO:0051049 regulation of transport 32.0E-3 8.83 166.00 
91 GO:0046903 secretion 2.9E-3 10.00 117.00 
92 GO:0032940 secretion by cell 630.0E-6 10.50 108.00 
93 GO:0007167 enzyme linked receptor protein signaling pathway 1.7E-3 10.34 106.00 
94 GO:0007166 cell surface receptor signaling pathway 2.6E-6 9.11 258.00 
95 GO:0010564 regulation of cell cycle process 5.6E-3 11.46 69.00 
96 GO:0048518 positive regulation of biological process 70.0E-9 8.31 455.00 
97 GO:0048522 positive regulation of cellular process 10.0E-9 8.56 418.00 
98 GO:0007165 signal transduction 19.0E-6 7.94 478.00 
99 GO:0048584 positive regulation of response to stimulus 1.1E-6 9.67 210.00 
100 GO:0048583 regulation of response to stimulus 1.6E-9 9.05 347.00 
101 GO:0023056 positive regulation of signaling 290.0E-6 9.62 159.00 
102 GO:0009967 positive regulation of signal transduction 500.0E-6 9.75 147.00 
103 GO:1902533 positive regulation of intracellular signal transduction 28.0E-3 10.00 96.00 
104 GO:0042327 positive regulation of phosphorylation 26.0E-3 9.99 98.00 
105 GO:0050730 regulation of peptidyl-tyrosine phosphorylation 41.0E-3 14.10 33.00 
106 GO:0050731 positive regulation of tyrosine phosphorylation 8.6E-3 16.11 29.00 
107 GO:0043408 regulation of MAPK cascade 18.0E-3 10.71 77.00 
108 GO:0001934 phosphorylation 17.0E-3 10.12 95.00 
109 GO:0071900 kinase activity 20.0E-3 11.72 58.00 
110 GO:0023014 phosphorylation 15.0E-3 10.10 97.00 
111 GO:0000165 MAPK cascade 27.0E-3 10.06 93.00 
112 GO:0016310 phosphorylation 190.0E-6 9.06 214.00 
113 GO:0051338 regulation of transferase activity 41.0E-3 9.84 98.00 
114 GO:0006793 phosphorus metabolic process 41.0E-3 8.11 266.00 
115 GO:0031401 process 41.0E-3 9.49 114.00 
117 GO:0036211 protein modification process 21.0E-3 7.98 315.00 
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7.12.2 Supplementary Table 2. Cell adhesion and EMT genes 
Input IDs Signal p-value Input IDs Signal p-value Input IDs Signal p-value 
ID2 3.51 1.25E-70 DVL3 0.644 1.23E-10 FZD8 0.8982 3.68E-05 
KRT8 2.706 7.27E-06 FZD1 0.6418 3.87E-05 TGIF1 0.9364 3.32E-20 
KRT18 2.229 0.0003449 TGFBR2 0.6328 2.4E-13 PARD6A 0.9551 0.02001 
ETS1 1.593 6.21E-65 PIK3R3 0.6296 1.72E-08 MET 0.9565 2.76E-26 
SOX9 1.52 9.26E-12 TSC2 0.6128 0.000115 CLDN1 0.9735 2.39E-14 
CDC42 1.484 1.2E-50 JUND 0.6121 2.63E-08 MAP2K3 1.016 1.12E-15 
SNAI2 1.42 2.11E-48 MKL2 0.6108 7.87E-09 OSMR 1.026 1.38E-27 
BMP4 1.383 0.00518 COL1A1 0.6088 0.01034 MUC1 1.032 5.93E-06 
JUN 1.345 6.77E-21 ACVR1 0.6003 1.53E-10 LOXL2 1.034 7.21E-14 
DVL2 1.298 1.21E-15 GNAI2 0.581 1.25E-07 IL6ST 1.044 6.5E-22 
MAP2K6 1.18 1.77E-16 SKIL 0.5897 9.36E-06 LIMK2 1.06 1.33E-26 
GAB1 1.052 
1.25E-22 
FRS2 0.5937 
9.46E-07 SERPINE
1 1.191 
0.000052 
RBPJ 0.9931 9.17E-21 TGFB1 0.5983 0.002243 DOCK2 1.193 2.11E-06 
ABL1 0.9532 5.2E-14 CHUK 0.6021 1.13E-07 ITGA2 1.281 1.35E-37 
BCL2 0.8421 9.85E-10 FARP2 0.6103 2.46E-09 PDK1 1.295 1.78E-35 
AKT1 0.8411 5.48E-08 MAP2K1 0.6541 4.45E-11 ITGB1 1.376 7.98E-51 
CALD1 0.7958 1.15E-18 ME2 0.6617 3.11E-11 FOS 1.395 8.18E-20 
ESR1 0.7935 0.02322 FN1 0.6625 1.92E-17 JUNB 1.448 2.09E-09 
PIK3CA 0.7797 8.69E-09 EGF 0.6981 2.58E-05 PTGS2 1.484 9.97E-06 
NFATC1 0.7536 9.77E-06 FZD5 0.6987 5.47E-06 PDGFB 1.555 2.23E-15 
TWIST1 0.7516 0.0000352 FZD7 0.722 1.09E-06 CYP19A1 1.557 3.76E-06 
MAP3K11 0.7473 0.0000293 HIF1A 0.7367 2.04E-16 NOX4 1.681 1.08E-47 
WNT5A 0.7379 
0.002297 
CTGF 
-
0.7695 
7.08E-16 
TGFBR1 1.708 
2.79E-60 
TJP1 0.6864 5.92E-13 CBL 0.7707 4.26E-14 S100A4 1.9 6.37E-10 
ILK 0.682 7.99E-13 MAP3K1 0.7879 4E-14 HLA-DQB 1.982 7.61E-11 
ACTG1 0.6554 
3.89E-13 RPS6KA
3 0.8256 
4.84E-20 
COL1A2 2.436 
2.68E-53 
SYP 0.6504 0.0002122 FOSL2 0.8312 1.08E-09 ACTG2 2.639 2.17E-05 
AKT2 0.6499 5.11E-06 RAF1 0.833 1.06E-19 FARP2 2.727 9.19E-11 
CFL1 0.6465 8.1E-13 HEY1 0.8471 2.42E-09    
 
  
 
 
 
92 
 
 
7.12.3 Supplementary Table 3 Overlapping genes with MITF and AXL Program 
 
Low vs High SMAD7(TCGA) siSMAD7 VS siCONTROL 
MITF Program AXL Program MITF Program AXL Program 
MLANA 3.361 UCN2 -3.425 PLK2 1.739 UBE2C 0.876 
RAB38 3.208 SLC16A6 -3.194 JUN 1.300 GADD45A 0.783 
ABCB5 3.008 TCN1 -2.173 CELF2 1.160 FSTL3 0.582 
HMCN1 3.361 CITED1 -2.116 IRF4 1.120 UPP1 1.854 
CDK2 3.252 ENO2 -2.054 APOE 0.937 FN1 1.250 
SLC7A5 2.821 UPP1 -1.794 ELOVL2 0.860 GLRX2 0.654 
VAT1 2.818 PFKFB4 -1.671 CYP27A1 0.856 UBE2J1 0.709 
PTPRZ1 2.786 ANGPTL4 1.043 LZTS1 0.856 RIN1 -0.709 
MLPH 2.458 GLRX 1.103 TFAP2A 0.855 SLC16A3 0.731 
TFAP2A 2.56 GEM 1.168 PLP1 0.736 ZYX 0.774 
TYR 2.36 IL18BP 1.251 ERBB3 0.718 P4HA2 0.775 
CDH1 2.346 SPATA13 1.277 C1orf85 0.645 GBE1 0.818 
TMEM98 1.987 FAM46A 1.292 SIRPA 0.640 NGFR 0.820 
GYG2 1.954 COL6A1 1.302 MYO10 0.620 C9orf89 0.821 
SLC24A5 1.877 LOXL2 1.352 VAT1 0.598 SH3BGRL3 0.832 
MITF 1.65 ZCCHC6 1.374 STAM 0.589 SLC25A37 0.871 
PIR 1.876 FGFRL1 1.391 SLC35B4 -.0.743 FOSL1 0.887 
SNCA 1.765 FN1 1.478 OSTM1 -0.903 TIMP1 0.892 
C1orf85 1.721 HAPLN3 1.492 IGSF8 -1.184 HPCAL1 0.900 
IGSF8 1.718 COL6A2 1.531 DNAJA4 -1.938 FAM46A 0.923 
GPR143 1.717 BACH1 1.555 FOSB -3.104 DBNDD2 0.933 
DNAJA4 1.678 CADM1 1.598 
  PHLDA2 0.953 
IGSF11 1.567 CRIP1 1.62 
  FGFRL1 1.026 
CHL1 1.423 SLC22A4 1.665   LOXL2 1.034 
QPCT 1.346 NNMT 1.717 
  TNFRSF12 1.073 
TBC1D7 1.325 S100A4 1.785 
  CD82 1.107 
JUN 1.45 AIM2 1.821 
  SEC14L2 1.134 
SIRPA 1.235 PMAIP1 1.836 
  S100A6 1.141 
CYP27A1 1.235 IGFBP3 1.876 
  CDKN1A 1.167 
TNFRSF1 1.234 MAP1B 1.942   SERPINE1 1.191 
SLC45A2 1.16 CD52 2.071   MT2A 1.335 
EXOSC4 1.168 SERPINE1 2.124   SLC2A1 1.338 
CAPN3 1.982 CHI3L1 2.139   ENO2 1.358 
LZTS1 1.152 AXL 2.242   CD109 1.368 
S100B 1.126 NGFR 2.259   ERO1L 1.142 
SLC19A2 1.123 CFB 2.456   AIM2 1.358 
ROPN1 0.765 STRA6 2.982   AXL 1.498 
FOSB 1.565     MAP1B 1.500 
DOCK10 1.855     PLAUR 1.796 
ELOVL2 2.346     NNMT 1.830 
      IL8 1.358 
      IGFBP3 1.358 
      GEM 3.632 
      UCN2 4.248 
      METTL7B 5.479 
      ANGPTL 1.358 
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7.12.4 Supplementary Table 4. Mouse Genotyping Primers 
Gene Forward Sequence (5'-3') Reverse Sequence (5'-3') 
Cre CTATCCAGCAACATTTGGGCCAGC CCAGGTTACGGATATAGTTCATGAC 
Ink4wt ATGATGATGGGCAACGTTC CAAATATCGCACGATGTC 
Ink4-/- CTATCAGGACATAGCGTTGG AGTGAGAGTTTGGGGACAGAG 
N-RasQ61K GATCCCACCATAGAGGATT CTGGCGTATTTCTCTTACC 
Smad4 wt GGCACATTACATTTGCAGTCAG AGGAAAAACAGGGCTATGTAGAA 
Smad4lox GGCACATTACATTTGCAGTCAG GACCCAAACGTCACCTTCAC 
Smad7wt TTCAGAGGCAGACCGAACCTCCAA AGGATTGGGTCAGGGACAGAAGAGCA 
Smad7lox TTCAGAGGCAGACCGAACCTCCAA TCTCACCTTGCTCCTGCCGAGAAAGTA 
LacZ GGTCGGCTTACGGCGGTGATTT AGCGGCGTCAGCAGTTGTTTTT 
 
7.12.5 Supplementary Table 5. Antibodies 
 
Secondary Antibodies 
Antigen Company Source Application / 
Dilutions 
Catalog Number 
Alexa 546 Jackson 
ImmunoResearch 
Mouse IF 1:250 A-1103 
Alexa 488 Jackson 
ImmunoResearch 
Rabbit IF 1:250 711-545-152 
Alexa 488 Jackson 
ImmunoResearch 
Goat IF 1:250 705-545-147 
Biotin-SP IgG Jackson 
ImmunoResearch 
Donkey IF 1:300 711-065-052 
Biotin-SP IgG Chemicon Chicken IF 1:300 AP194B 
Streptavidin HRP Jackson 
ImmunoResearch 
Goat IF 1:300 016-030-084 
IRDye-800CW Li-COR Biosciences Donkey WB 1:10000 926-32214 
IRDye-680LT Li-COR Biosciences Mouse WB 1:10000 926-68023 
 
Primary Antibodies 
 
Antigen Company Source Application / 
Dilutions 
Catalog Number 
β-actin Sigma- Aldrich Mouse WB 1:10000 A-5316 
α-tubulin Sigma- Aldrich Mouse WB 1:10000 T-6074 
β -Gal. Abcam Chicken IF 1:1000 ab9361 
Axl Santa Cruz ca Goat WB 1:50 IF 1:100 sc-1096 
Caspase3 Cell Signaling Technology Rabbit IF 1:200 9661 
DCT Santa Cruz Biotechnology Goat IF 1:250 sc-10451 
HMB45 Abcam Mouse IF 1:200 ab732 
pSMAD2/3 Santa Cruz Goat IF 1:300 sc-11769 
pSMAD2 Cell Signaling Technology Rabbit WB 1:50 IF 1:300 3101 
pSMAD1/5/8 Cell Signaling Technology Rabbit WB 1:50 IF 1:300 9511S 
SMAD2 Cell Signaling Technology Rabbit WB 1:100 5339 
SMAD1 Cell Signaling Technology Rabbit WB 1:50 9743 
PAX3 Invitrogen Rabbit IF 1:300 38081 
SMAD7 Santa Cruz Goat IF 1:300 sc-9183 
SMAD4 Abcam Rabbit IF 1:300 ab40759 
Ki67 Abcam Rabbit IF 1:50 ab15580 
MiTF Santa Cruz Rabbit IF: 1:200 WB 1:200 sc-56726 
 
 
 
94 
 
7.12.6 Supplementary Table 6. siRNAs and Primer sequences 
Forward and reverse primer sequences used in qPCR and the sequences of the siRNAs aimed against 
the different SMADs 
Human(siRNA) 
Gene Company Target Exon siRNA Location Catalog Number 
siSMAD7 #1 Life Technologies Human 3,4 1028 HSS106264 
siSMAD7 #2 Life Technologies Human 4 1426 HSS180976 
siSMAD4 #1 Life Technologies Human 9,10 1582 HSS106255 
siSMAD4 #2 Life Technologies Human 5 1088 HSS180973 
siControl Med.GC Life Technologies   129353003 
 
Human (RT-PCR Primers) 
Genes Forward Sequence (5'-3') Reverse Sequence (5'-3') 
ACTIN AGAGCTACGAGCTGCCTGAC AGCACTGTGTTGGCGTACAG 
AXL GCTGTCAGACGATGGGATG CCATTCCGCGTAGCACTAA 
GAPDH AATCCCATCACATCTTCC CATCACGCCACAGTTTCC 
ZEB1 TGCACTGAGTGTGGAAAAGC TGGTGATGCTGAAAGAGACG 
TWIST1 ACCATCCTCACACCTCTGCATT TGCAGGCTTTGATCCCAGTAT 
ZEB2 CGCTTGACATCACTGAAGGA CTTGCCACACTCTGTGCATT 
SNAIL2 AGCAAGAAGTCGAGCGAAGA CAGCTTGAGCGTCTGGATCT 
CDH1 CTGCTGCCACCAGATGATGA CTGTGCAGCTGGCTCAAATC 
CDH271 CCT ACGGCTACTACCAGGATG CACACGGTGTTCTGCTTGT 
MITF CAGGCATGAACACACATTCAC TCCATCAAGCCCAAGATTTC 
VIM GAGAACTTTGCCGTTGAAGC GCTTCCTGTAGGTGGCAATC 
FN1 AAACCAATTCTTGGAGCAGG CCATAAAGGGCAACCAAGAG 
LOXL2 TGACGACTTCTCCATCCACG GGAATCCTTTTGTCGCTGCA 
SERPINE1 CATGTTCATTGCTGCCCCTT CGGTCATTCCCAGGTTCTCT 
AXL GCTGTCAGACGATGGGATG CCATTCCGCGTAGCACTAAT 
SIRPa GCTCTCAGACTTCCAGACC GTGGAACTCGGATGGTCTCA 
CDK2 TTCTGCCATTCTCATCGGGT AGGAGGATTTCAGGAGCTCG 
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Mouse (RT-PCR Primers) 
Genes  Forward Sequence (5'-3') Reverse Sequence (5'-3') 
Actin  GACGGGGTCACCCACACTGTGCCCATCTA CTAGAAGCATTTGCGGTGGACGATGGAGG 
Gapdh  AATCCCATCACATCTTCC CATCACGCCACAGTTTCC 
Zeb1  TGCACTGAGTGTGGAAAAGC TGGTGATGCTGAAAGAGACG 
Twist1  ACCATCCTCACACCTCTGCATT TGCAGGCCAGTTTGATCCCAGTAT 
Zeb2  CGCTTGACATCACTGAAGGA CTTGCCACACTCTGTGCATT 
Snail2  AGCAAGAAGTCGAGCGAAGA CAGCTTGAGCGTCTGGATCT 
Cdh1  CTGCTGCCACCAGATGATGA CTGTGCAGCTGGCTCAAATC 
Cdh271  TGCTGTTGCTGCTTCTGG CTCACACACGGTCTGGTTG 
Vim  GAGAACTTTGCCGTTGAAGC GCTTCCTGTAGGTGGCAATC 
Bmp7  ATT TCA GCC TGG ACA ACG AG AGACGGCCTTGTAGGGGTAG 
Nodal  ACTTTGCTTTGGGAAGCTGA AGGAGGGTCAAGTTCCAGGT 
Tgfβ2  TGCCAGTGGTGATCAGAA AA TCCATTTCCATCCAAGATCC 
Fn1  AAACCAATTCTTGGAGCAGG CCATAAAGGGCAACCAAGAG 
 
7.12.7 Supplementary Table 7. Ligand information 
Ligand Company Source Application  Catalog Number  
TGF-β1 R&D Systems Human 10 ng/µl 240-B-010  
TGF-β2 Peprotech Human 5-10 ng/µl 100-35B  
ACTIVIN R&D Systems Human 50 ng/µl 338-AC-010  
NODAL R&D Systems Human 100 ng/µl 3218-ND-025  
BMP2 Peprotech Human 50 ng/µl 120-02  
BMP4 R&D Systems Human 50 ng/µl 314-BP  
BMP7 R&D Systems Human 100 ng/µl 354-BP  
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8. Discussion 
Phenotype switching, i.e. the reversible switch from a proliferative MITFhigh/AXLlow melanoma cell to 
an invasive MITFlow/AXLhigh cell, is thought to represent a key mechanism underlying melanoma 
progression (Keith S. Hoek & Goding 2010; Müller et al. 2014; Chapman et al. 2014). In the present 
study, however, we demonstrate that phenotype switching is not obligatory for invasion and metastatic 
spread of melanoma cells and that invasive melanoma cells can overcome restrictions in proliferation 
by intrinsically modulating their response to combinatorial TGF- β  superfamily signaling. Despite the 
vast literature on TGF- β  eliciting an anti-proliferative and pro-invasive effect in melanoma cells 
(Rodeck et al. 1999; Janji et al. 1999; Miyoshi et al. 1995), we reveal that Smad4-mediated overall 
canonical TGF- β signaling is required for tumor initiation and primarily promotes, rather than 
antagonizes, melanoma cell proliferation in vivo. Consistent with these data, we identify BMP7 as a 
factor stimulating melanoma cell proliferation and able to override the anti-proliferative/pro-invasive 
activity of TGF- β and NODAL. However, invasiveness can be triggered in these cells by lowering 
levels of the inhibitory SMAD protein SMAD7. Strikingly, activation of integrated TGF- β signaling 
by SMAD7 inhibition results in the emergence of an invasive program characterized by high AXL and 
ZEB1 expression in cells maintaining high MITF expression and proliferative capacity. Consequently, 
the increase in the number of Mitfhigh/Axlhigh cells in Smad7-depleted melanoma is associated with 
massive metastasis formation in vivo. Our findings demonstrate that proliferation is compatible with 
increased invasiveness and continued expression of MITF and reveal a novel mechanism underpinning 
melanoma aggressiveness. 
 
Our data are compatible with earlier studies suggesting that melanoma progression can occur in the 
absence of phenotype switching. Recently, single cell RNA sequencing revealed the presence of a small 
subpopulation of MITFhigh/AXLhigh cells in every human tumor sample assessed, although MITF and 
AXL expression were exclusive on the level of the bulk tumor (Tirosh et al. 2016). Likewise, a 
considerable fraction of circulating tumor cells isolated from invasive melanoma patients was MITF 
positive (Khoja et al. 2014). Widmer and colleagues showed that in cultures of melanoma cells, hypoxia 
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could drive invasion without affecting overall proliferation (Widmer et al. 2013). Furthermore, cells in 
invasive cell clusters did not alter MITF expression during a process referred to as cooperative invasion 
(Chapman et al. 2014). Finally, time-lapse microscopy in vitro and ex vivo demonstrated that invading 
melanoma cells in culture do not necessarily undergo cell cycle arrest and actively proliferate regardless 
of their MITF expression status (Haass et al. 2014). Our study now reveals how a cellular state of 
simultaneous proliferation and invasion can be achieved by modulation of combinatorial TGF- β  
signaling in melanoma cells. Conceivably, changes in overall TGF- β  signal activity and thus 
emergence of invasive-proliferative MITFhigh/AXLhigh cells during melanoma progression are 
dependent on the availability of growth factors, nutrients and/or oxygen in the microenvironment, 
although this needs to be addressed in future studies. 
 
It is well established that the biological effects of TGF-β superfamily signaling are context-dependent, 
but how specific responses to TGF- β  family factors are controlled is still largely unknown (Massagué 
2012). In melanoma, several TGF- β  superfamily factors, including TGF- β , ACTIVINA, NODAL, 
BMP2, BMP4, and BMP7 are known to be expressed and to activate signaling in an autocrine manner 
(Topczewska et al. 2006; Hsu et al. 2005; Perrot et al. 2013; Lázár-Molnár et al. 2000; Stove et al. 
2004). However, BMP7 promoted proliferation, whereas BMP4 induced cell cycle arrest in melanoma 
cells at concentrations at which both factors activated the pSMAD1/5/8-branch of TGF-β signaling to 
a comparable extent. In agreement with other studies (Schlegel et al. 2009; Schlegel et al. 2015; Hendrix 
et al. 2007) cell cycle arrest was also induced upon treatment with either TGF-β or NODAL, which 
unlike BMP4 act through pSMAD2/3 rather than pSMAD1/5/8. Of note, however, nuclear pSMAD2/3 
activity is not only present in TGFβ-treated arrested cells, but also readily detectable in proliferative 
melanoma cells in vitro and in vivo (Rodeck et al. 1999; Schlegel et al. 2015; Lo & Witte 2008). 
Furthermore, loss of SMAD7 enhanced both pSMAD1/5/8 and pSMAD2/3 levels in melanoma cell 
cultures and in our melanoma mouse model, but predominantly boosted TGF- β /NODAL-induced 
invasiveness rather than BMP7-induced proliferation. Thus, the phenotype obtained upon reducing 
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SMAD7 in the context of combinatorial TGF-β superfamily signaling cannot simply be explained by 
preferential usage of either pSMAD2/3 or pSMAD1/5/8 signaling.  
 
Our finding that BMP7 acts as a pro-proliferative factor in melanoma even in the presence TGF-
β/pSMAD2/3 signaling is in line with studies in systems other than melanoma, in which BMP7 was 
reported to override effects of TGF- β . For instance, TGF-β/NODAL and BMP7 counter-regulate each 
other during pathophysiological processes in various organs, such as lung, liver, and kidney (Pegorier 
et al. 2010; Zeisberg et al. 2003; Zeisberg et al. 2007). In breast cancer cells, BMP7 inhibits expression 
of TGFβ-activated genes associated with epithelial-mesenchymal transition (EMT), resulting in a 
significant reduction in TGFβ-triggered cell migration and invasiveness in culture (Ying et al. 2015), 
reminiscent of our findings in melanoma. It remains to be shown whether in these cases the balance 
between integrated BMP7- and TGF-β-dependent signaling outcome can be tipped by modulation of 
SMAD7 activity in a manner similar to what we observed in melanoma, where an EMT gene expression 
signature, loss of cell-substrate adhesion in vitro, and metastasis formation in vivo were all promoted 
upon SMAD7 inactivation in spite of the presence of BMP7 and pSmad1/5/8 activity. 
 
Our experiments indicate that overall canonical TGF-β/SMAD signaling is a potent promoter of 
melanoma progression, already at early stages of the disease. Eliminating the common downstream 
signaling mediator Smad4 in our murine melanoma model did not interfere with normal melanocyte 
survival, but counteracted NrasQ61K-driven hyperpigmentation and melanoma initiation. Taking 
advantage of an inducible system allowing gene manipulation at various stages of tumor progression, 
we also show that Smad4 is required for proliferation in established skin melanoma, revealing the 
existence of and necessity for pro-proliferative activators of the Smad pathway, such as BMP7, for 
melanoma propagation. Since pro-proliferative BMP7 appears to be dominant over pro-invasive factors, 
the question arises of how a metastatic process is induced in melanoma. One possible mechanism might 
involve spatiotemporal changes in the composition of the TGF-β superfamily factors to which a tumor 
cell is exposed, where reducing levels of pro-proliferative factors relative to pro-invasive factor 
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concentrations would promote the development of invasive cells with limited proliferation capacity 
(Hölzel & Tüting 2016). Whether such phenotype switching indeed occurs in vivo remains to be shown. 
Our study offers an alternative mechanism of metastasis formation, which involves the reduction of 
SMAD7 levels in the presence of pro-proliferative and pro-invasive TGF-β superfamily factors. 
Although it is currently unknown how SMAD7 expression is normally regulated in melanoma, targeting 
SMAD7 level-dependent emergence of proliferative cells with metastatic capacity might represent a 
powerful treatment strategy, possibly in combination with drugs interfering with tumor cell 
proliferation. Indeed, high levels of ZEB1 expression, which we show to be induced by SMAD7 
inactivation, have been associated with inherent resistance to MAPKi in BRAFV600E-mutant melanoma 
(Richard et al. 2016). Likewise, a shift towards AXLhigh expression was observed in melanoma samples 
resistant to RAF and MEK inhibition, whereas high expression of MITF in melanoma cells confers high 
sensitivity to MAPK pathway inhibition (Tirosh et al. 2016; Müller et al. 2014). Importantly, our study 
provides a system for investigating how tumor cell intrinsic changes independent of phenotype witching 
contribute to malignant progression of melanoma. 
In our genetic murine model melanoma is initiated and grow spontaneously in a 3D environment 
together with tumor microenvironment elements. Therefore, an inducible conditional knockout strategy 
in these mice allowed us studying functional role of SMAD signaling.  Few studies have also taken 
advantage of cKO models of melanoma, although most of the research on gene function in melanoma 
are based on cell culture and transplantation assays. Importantly, genes shown to be involved in 
melanoma formation turned out to be also important for normal melanocyte biology. For instance TGF-
B signaling has been shown to be required for melanoma stem cell maintenance at the bulge. (Nishimura 
et al. 2006) as well as crucial for complete differentiation process. During my Phd, I found that TGF-B 
signaling is required for melanoma growth and metastasis. Deletion of Smad4 completely prevents 
melanoma initiation without affecting the normal melanocyte homeostasis (Data is not shown). This 
suggest that in melanoma SMAD signaling plays unique tumor specific role.  
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8.1 Current Model 
 
Current Model. Reduced SMAD7 levels in the context of complex TGF-β superfamily signaling increases 
the invasive potential of melanoma cells while sustaining their proliferative capacity.  Loss of Smad7 in the 
presence of pro-proliferative and pro-invasive ligands leads to an increase in number of Mitf High Axl High cells 
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